Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российского научного медицинского общества терапевтов, Российского общества профилактики неинфекционных заболеваний, Российского научного медицинского общества терапевтов, Российского общества клинической онкологии, Научного сообщества по изучению микробиома человека по лекарственным поражениям печени

Цель представления: клинических рекомендаций заключается в обеспечении информационной поддержки для принятия врачами-гастроэнтерологами, врачами общей практики и врачами-терапевтами решений, способствующих повышению качества оказания медицинской помощи пациенту с лекарственными поражениями печени, с учетом новейших клинических данных и принципов доказательной медицины.

Основное содержание. Клинические рекомендации содержат информацию о современных представлениях об этиологии, факторах риска и патогенезе лекарственных поражений печени, особенностях их клинического течения. Также в рекомендациях представлена информация об актуальных методах лабораторной и инструментальной, инвазивной и неинвазивной диагностики лекарственных поражений печени и их клинических фенотипов, подходах к их лечению с учетом наличия коморбидностей, особенностей диспансерного наблюдения и профилактики. Приведенная информация проиллюстрирована алгоритмами дифференциального диагноза, действий врача. Помимо этого, присутствует информация для пациента и критерии оценки качества оказания медицинской помощи.

Заключение. Осведомленность специалистов в вопросах диагностики, лечения и наблюдения пациентов с лекарственными поражениями печени способствует своевременной постановке диагноза и инициации лечения, что в отдаленной перспективе будет существенно влиять на их прогноз и качество жизни.

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222–61. DOI: 10.1016/j.jhep.2019.02.014

2. Fontana R.J., Liou I., Reuben A., Suzuki A., Fiel M.I., Lee W., et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023;77(3):1036–65. DOI: 10.1002/hep.32689

3. Chen M., Suzuki A., Borlak J., Andrade R.J., Lucena M.I. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol. 2015;63(2):503–14. DOI: 10.1016/j.jhep.2015.04.016

4. Council for International Organizations of Medical Sciences (CIOMS). Drug-induced liver injury (DILI): Current status and future directions for drug development and the post-market setting. Geneva, 2020. URL: https://cioms.ch/wp-content/uploads/2020/06/CIOMS_DILI_Web_16Jun2020.pdf

5. Hoofnagle J.H., Björnsson E.S. Drug-induced liver injury — types and phenotypes. N Engl J Med. 2019;381(3):264–73. DOI: 10.1056/NEJMra1816149

6. Li M., Wang Y., Lv T.T., Liu J.M., Kong Y.Y., Jia J.D., et al. Mapping the incidence of drug-induced liver injury: A systematic review and meta-analysis. J Dig Dis. 2023;24(5):332–9. DOI: 10.1111/1751-2980.13205

7. Lucena M.I., Sanabria J., García-Cortes M., Stephens C., Andrade R.J. Drug-induced liver injury in older people. Lancet Gastroenterol Hepatol. 2020;5(9):862–74. DOI: 10.1016/S2468-1253(20)30006-6

8. Yu S., Li J., He T., Zheng H., Wang S., Sun Y., et al. Age-related differences in drug-induced liver injury: A retrospective single-center study from a large liver disease specialty hospital in China, 2002–2022. Hepatol Int. 2024;18(4):1202–13. DOI: 10.1007/s12072-024-10679-1

9. Lucena M.I., Andrade R.J., Kaplowitz N., GarcíaCortes M., Fernández M.C., Romero-Gomez M., et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. Hepatology. 2009;49(6):2001–9. DOI: 10.1002/hep.22895

10. Chalasani N., Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138(7):2246–59. DOI: 10.1053/j.gastro.2010.04.001

11. Andrade R.J., Lucena M.I., Fernández M.C., Pelaez G., achkoria K., García-Ruiz E., et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21. DOI: 10.1016/j.gastro.2005.05.006

12. Reuben A., Koch D.G., Lee W.M.; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52(6):2065–76. DOI: 10.1002/hep.23937

13. Chalasani N.P., Maddur H., Russo M.W., Wong R.J., Reddy K.R.; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: Diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021;116(5):878–98. DOI: 10.14309/ajg.0000000000001259

14. Ивашкин В.Т., Барановский А.Ю., Райхельсон К.Л., Пальгова Л.К., Маевская М.В., Кондрашина Э.А. и др. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):85–115. DOI: 10.22416/1382-4376-2019-29-1-101-131

15. Daly A.K. Genetics of drug-induced liver injury: Current knowledge and future prospects. Clin Transl Sci. 2023;16(1):37–42. DOI: 10.1111/cts.13424

16. Cirulli E.T., Nicoletti P., Abramson K., Andrade R.J., Bjornsson E.S., Chalasani N., et al.; Drug-Induced Liver Injury Network (DILIN) investigators; International DILI consortium (iDILIC). A missense variant in PTPN22 is a risk factor for drug-induced liver injury. Gastroenterology. 2019;156(6):1707–16.e2. DOI: 10.1053/j.gastro.2019.01.034

17. Hautekeete M.L., Horsmans Y., Van Waeyenberge C., Demanet C., Henrion J., Verbist L., et al. HLA association of amoxicillin-clavulanate — induced hepatitis. Gastroenterology. 1999;117(5):1181–6. DOI: 10.1016/s0016-5085(99)70404-x

18. Huang Y.S., Chern H.D., Su W.J., Wu J.C., Lai S.L., Yang S.Y., et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002;35(4):883–9. DOI: 10.1053/jhep.2002.32102

19. Nicoletti P., Devarbhavi H., Goel A., Venkatesan R., Eapen C.E., Grove J.I., et al. Genetic risk factors in drug-induced liver injury due to isoniazid-containing antituberculosis drug regimens. Clin Pharmacol Ther. 2021;109(4):1125–35. DOI: 10.1002/cpt.2100

20. Hayashi P.H., Rockey D.C., Fontana R.J., Tillmann H.L., Kaplowitz N., Barnhart H.X., et al.; Drug-Induced Liver Injury Network (DILIN) Investigators. Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology. 2017;66(4):1275–85. DOI: 10.1002/hep.29283

21. Andrade R.J., López-Ortega S., López-Vega M.C., Robles M., Cueto I., Lucena M.I. Idiosyncratic drug hepatotoxicity: A 2008 update. Expert Rev Clin Pharmacol. 2008;1(2):261–76. DOI: 10.1586/17512433.1.2.261

22. Dakhoul L., Ghabril M., Gu J., Navarro V., Chalasani N., Serrano J.; United States Drug Induced Liver Injury Network. Heavy consumption of alcohol is not associated with worse outcomes in patients with idiosyncratic drug-induced liver injury compared to non-drinkers. Clin Gastroenterol Hepatol. 2018;16(5):722–9.e2. DOI: 10.1016/j.cgh.2017.12.036

23. Van Roey G., Goos W., Claessens C., Hoorens A., Verlinden W., Schouten J. Acute grade IV toxic hepatitis due to the e-cigarette. Acta Gastroenterol Belg. 2024;87(1):44–7. DOI: 10.51821/87.1.11378

24. Liu A., Walter M., Wright P., Bartosik A., Dolciami D., Elbasir A., et al. Prediction and mechanistic analysis of drug-induced liver injury (DILI) based on chemical structure. Biol Direct. 2021;16(1):6. DOI: 10.1186/s13062-020-00285-0

25. Zhang H., Ding L., Zou Y., Hu S.Q., Huang H.G., Kong W.B., et al. Predicting drug-induced liver injury in human with Naïve Bayes classifier approach. J Comput Aided Mol Des. 2016;30(10):889–98. DOI: 10.1007/s10822-016-9972-6

26. Pessayre D., Fromenty B., Berson A., Robin M.A., Lettéron P., Moreau R., et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev. 2012;44(1):34–87. DOI: 10.3109/03602532.2011.604086

27. Albrecht W., Kappenberg F., Brecklinghaus T., Stoeber R., Marchan R., Zhang M., et al. Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations. Arch Toxicol. 2019;93(6):1609–37. DOI: 10.1007/s00204-019-02492-9

28. Sandhu N., Navarro V. Drug-induced liver injury in GI practice. Hepatol Commun. 2020;4(5):631–45. DOI: 10.1002/hep4.1503

29. Lin J., Li M., Mak W., Shi Y., Zhu X., Tang Z., et al. Applications of in silico models to predict drug-induced liver injury. Toxics. 2022;10(12):788. DOI: 10.3390/toxics10120788

30. Lee K.S., Oh S.J., Kim H.M., Lee K.H., Kim S.K. Assessment of reactive metabolites in drug-induced liver injury. Arch Pharm Res. 2011;34(11):1879–86. DOI: 10.1007/s12272-011-1108-x

31. Onfiani G., Nascimbeni F., Carubbi F. A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect? J Basic Clin Physiol Pharmacol. 2021;32(6):1151–5. DOI: 10.1515/jbcpp-2021-0013

32. De Abajo F.J., Montero D., Madurga M., García Rodríguez L.A. Acute and clinically relevant drug-induced liver injury: A population based case-control study. Br J Clin Pharmacol. 2004;58(1):71–80. DOI: 10.1111/j.1365-2125.2004.02133.x

33. Björnsson E.S., Bergmann O.M., Björnsson H.K., Kvaran R.B., Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–25. DOI: 10.1053/j.gastro.2013.02.006

34. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22(2):145–55. DOI: 10.1055/s-2002-30105

35. Low E.X.S., Zheng Q., Chan E., Lim S.G. Drug induced liver injury: East versus West — a systematic review and meta-analysis. Clin Mol Hepatol. 2020;26(2):142–54. DOI: 10.3350/cmh.2019.1003

36. Meier Y., Cavallaro M., Roos M., Pauli-Magnus C., Folkers G., Meier P.J., et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol. 2005;61(2):135–43. DOI: 10.1007/s00228-004-0888-z

37. Idilman R., Bektas M., Cinar K., Toruner M., Cerit E.T., Doganay B., et al. The characteristics and clinical outcome of drug-induced liver injury: A single-center experience. J Clin Gastroenterol. 2010;44(6):e128–32. DOI: 10.1097/MCG.0b013e3181c5e9cc

38. Licata A. Adverse drug reactions and organ damage: The liver. Eur J Intern Med. 2016;28:9–16. DOI: 10.1016/j.ejim.2015.12.017

39. Byeon J.H., Kil J.H., Ahn Y.C., Son C.G. Systematic review of published data on herb induced liver injury. J Ethnopharmacol. 2019;233:190–6. DOI: 10.1016/j.jep.2019.01.006

40. Wang J., Ma Z., Niu M., Zhu Y., Liang Q., Zhao Y., et al. Evidence chain-based causality identification in herb-induced liver injury: Exemplification of a well-known liver-restorative herb Polygonum multiflorum. Front Med. 2015;9(4):457–67. DOI: 10.1007/s11684-015-0417-8

41. Byeon J.H., Kil J.H., Ahn Y.C., Son C.G. Systematic review of published data on herb induced liver injury. J Ethnopharmacol. 2019;233:190–6. DOI: 10.1016/j.jep.2019.01.006

42. Райхельсон К.Л., Пальгова Л.К., Кондрашина Э.А., Марченко Н.В., Барановский А.Ю. Лекарственные поражения печени: клинические рекомендации для врачей. СПб., 2017.

43. Brennan P.N., Cartlidge P., Manship T., Dillon J.F. Guideline review: EASL clinical practice guidelines: Drug-induced liver injury (DILI). Frontline Gastroenterol. 2021;13(4):332–6. DOI: 10.1136/flgastro-2021-101886

44. Драпкина О.М., Маев И.В., Ахмедов В.А., Вологжанина Л.Г., Долгушина А.И., Игумнова О.А. и др. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2024;12:5–48. DOI: 10.31146/1682-8658-ecg-232-12-5-48

45. Mao Y., Ma S., Liu C., Liu X., Su M., Li D., et al.; Technology Committee on DILI Prevention, Management, Chinese Medical Biotechnology Association; Study Group on Drug-Induced Liver Disease, Chinese Society of Hepatology, Chinese Medical Association. Chinese guideline for the diagnosis and treatment of drug-induced liver injury: An update. Hepatol Int. 2024;18(2):384–419. DOI: 10.1007/s12072-023-10633-7

46. Kleiner D.E. The pathology of drug-induced liver injury. Semin Liver Dis. 2009;29(4):364–72. DOI: 10.1055/s-0029-1240005

47. Kleiner D.E., Chalasani N.P., Lee W.M., Fontana R.J., Bonkovsky H.L., Watkins P.B., et al.; Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations. Hepatology. 2014;59(2):661–70. DOI: 10.1002/hep.26709

48. Zhang X., Ouyang J., Thung S.N. Histopathologic manifestations of drug-induced hepatotoxicity. Clin Liver Dis. 2013;17(4):547–64. DOI: 10.1016/j.cld.2013.07.004

49. Bonkovsky H.L., Kleiner D.E., Gu J., Odin J.A., Russo M.W., Navarro V.M., et al.; U.S. Drug Induced Liver Injury Network Investigators. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 2017;65(4):1267– 77. DOI: 10.1002/hep.28967

50. Rabinowich L., Shibolet O. Drug induced steatohepatitis: An uncommon culprit of a common disease. Biomed Res Int. 2015;2015:168905. DOI: 10.1155/2015/168905

51. Goodman Z.D. Drug hepatotoxicity. Clin Liver Dis. 2002;6(2):381–97. DOI: 10.1016/s1089-3261(02)00011-9

52. Lu H.C., González I.A., Byrnes K. Ground-glass hepatocellular inclusions are associated with polypharmacy. Ann Diagn Pathol. 2021;52:151740. DOI: 10.1016/j.anndiagpath.2021.151740

53. Bessone F., Dirchwolf M., Rodil M.A., Razori M.V., Roma M.G. Review article: Drug-induced liver injury in the context of nonalcoholic fatty liver disease — a physiopathological and clinical integrated view. Aliment Pharmacol Ther. 2018;48(9):892–913. DOI: 10.1111/apt.14952

54. Kleiner D.E. Liver histology in the diagnosis and prognosis of drug-induced liver injury. Clin Liver Dis (Hoboken). 2014;4(1):12–6. DOI: 10.1002/cld.371

55. Björnsson E., Kalaitzakis E., Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2007;25(12):1411–21. DOI: 10.1111/j.1365-2036.2007.03330.x

56. Aithal G.P., Watkins P.B., Andrade R.J., Larrey D., Molokhia M., Takikawa H., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–15. DOI: 10.1038/clpt.2011.58

57. Fontana R.J., Seeff L.B., Andrade R.J., Björnsson E., Day C.P., Serrano J., et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: Summary of a clinical research workshop. Hepatology. 2010;52(2):730–42. DOI: 10.1002/hep.23696

58. Andrade R.J., Aithal G.P., de Boer Y.S., Liberal R., Gerbes A., Regev A., et al.; IAIHG and EASL DHI- LI Consortium. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report. J Hepatol. 2023;79(3):853–66. DOI: 10.1016/j.jhep.2023.04.033

59. García-Cortés M., Ortega-Alonso A., Matilla-Cabello G., Medina-Cáliz I., Castiella A., Conde I., et al. Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries. Liver Int. 2023;43(8):1749–60. DOI: 10.1111/liv.15623

60. Björnsson E., Talwalkar J., Treeprasertsuk S., Kamath P.S., Takahashi N., Sanderson S., et al. Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis. Hepatology. 2010;51(6):2040–8. DOI: 10.1002/hep.23588

61. De Boer Y.S., Kosinski A.S., Urban T.J., Zhao Z., Long N., Chalasani N., et al.; Drug-Induced Liver Injury Network. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol. 2017;15(1):103–2.e2. DOI: 10.1016/j.cgh.2016.05.043

62. Licata A., Maida M., Cabibi D., Butera G., Macaluso F.S., Alessi N., et al. Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. Dig Liver Dis. 2014;46(12):1116–20. DOI: 10.1016/j.dld.2014.08.040

63. Perdices E.V., Medina-Cáliz I., Hernando S., Ortega A., Martín-Ocaña F., Navarro J.M., et al. Hepatotoxicity associated with statin use: Analysis of the cases included in the Spanish Hepatotoxicity Registry. Rev Esp Enferm Dig. 2014;106(4):246–54.

64. Björnsson E.S., Medina-Caliz I., Andrade R.J., Lucena M.I. Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports. Hepatol Commun. 2022;6(8):1895–909. DOI: 10.1002/hep4.1959

65. Codoni G., Kirchner T., Engel B., Villamil A.M., Efe C., Stattermayer A.F., et al. Histological and serological features of acute liver injury after SARS-CoV-2 vaccination. JHEP Rep. 2023;5(1):100605. DOI: 10.1016/j.jhepr.2022.100605

66. Xu Z., Qi G., Liu X., Li Z., Zhang A., Ma J., et al. Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014–2021. PLoS One. 2023;18(3):e0281983. DOI: 10.1371/journal.pone.0281983

67. Lohse A.W., Sebode M., Bhathal P.S., Clouston A.D., Dienes H.P., Jain D., et al. Consensus recommendations for histological criteria of autoimmune hepatitis from the international AIH pathology group: Results of a workshop on AIH histology hosted by the European reference network on hepatological diseases and the European society of pathology: results of a workshop on AIH histology hosted by the European reference network on hepatological diseases and the European society of pathology. Liver Int. 2022;42(5):1058–69. DOI: 10.1111/liv.15217

68. García-Cortés M., Pinazo-Bandera J.M., Lucena M.I., Andrade R.J. Drug-induced autoimmune-like hepatitis. Clin Liver Dis (Hoboken). 2024;23(1):e0172. DOI: 10.1097/CLD.0000000000000172

69. Calle A.M., Aguirre N., Ardila J.C., Cardona Villa R. DRESS syndrome: A literature review and treatment algorithm. World Allergy Organ J. 2023;16(3):100673. DOI: 10.1016/j.waojou.2022.100673

70. Kardaun S.H., Sekula P., Valeyrie-Allanore L., Liss Y., Chu C.Y., Creamer D., et al.; RegiSCAR study group. Drug reaction with eosinophilia and systemic symptoms (DRESS): An original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071–80. DOI: 10.1111/bjd.12501

71. De A., Rajagopalan M., Sarda A., Das S., Biswas P. Drug reaction with eosinophilia and systemic symptoms: An update and review of recent literature. Indian J Dermatol. 2018;63(1):30–40. DOI: 10.4103/ijd.IJD_582_17

72. Choudhary S., McLeod M., Torchia D., Romanelli P. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Clin Aesthet Dermatol. 2013;6(6):31–7.

73. Alphonce B., Komanya F., Magitta N.F., Deodatus S., Sindato E. Amoxicillin-induced DRESS syndrome without eosinophilia. Clin Case Rep. 2024;12(8):e9333. DOI: 10.1002/ccr3.9333

74. Chen Y.C., Chang C.Y., Cho Y.T., Chiu H.C., Chu C.Y. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: A retrospective cohort study from Taiwan. J Am Acad Dermatol. 2013;68(3):459–65. DOI: 10.1016/j.jaad.2012.08.009

75. Takinami M., Ono A., Kawabata T., Mamesaya N., Kobayashi H., Omori S., et al. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. Invest New Drugs. 2021;39(6):1716–23. DOI: 10.1007/s10637-021-01136-z

76. Tew A., Khoja L., Pallan L., Steven N. Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series. J Oncol Pharm Pract. 2023;29(5):1163– 71. DOI: 10.1177/10781552221103548

77. Onoyama T., Takeda Y., Yamashita T., Hamamoto W., Sakamoto Y., Koda H., et al. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol. 2020;26(3):353–65. DOI: 10.3748/wjg.v26.i3.353

78. Sundaram V., Björnsson E.S. Drug-induced cholestasis. Hepatol Commun. 2017;1(8):726–35. DOI: 10.1002/hep4.1088

79. Gudnason H.O., Björnsson H.K., Gardarsdottir M., Thorisson H.M., Olafsson S., Bergmann O.M., et al. Secondary sclerosing cholangitis in patients with drug-induced liver injury. Dig Liver Dis. 2015;47(6):502–7. DOI: 10.1016/j.dld.2015.03.002

80. Bjornsson E.S., Devarbhavi H.C. Drug-induced cholestatic liver diseases. Hepatology. 2025;82(4):996–1015. DOI: 10.1097/HEP.0000000000001052

81. Bessone F., Hernández N., Tanno M., Roma M.G. Drug-induced vanishing bile duct syndrome: From pathogenesis to diagnosis and therapeutics. Semin Liver Dis. 2021;41(3):331–48. DOI: 10.1055/s-0041-1729972

82. Visentin M., Lenggenhager D., Gai Z., Kullak-Ublick G.A. Drug-induced bile duct injury. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt B):1498–506. DOI: 10.1016/j.bbadis.2017.08.033

83. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. URL: https://www.ncbi.nlm.nih.gov/books/NBK547852/

84. Stevenson H.L., Prats M.M., Sasatomi E. Chemotherapy-induced Sinusoidal Injury (CSI) score: A novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis. BMC Cancer. 2017;17(1):35. DOI: 10.1186/s12885-016-2998-2

85. Overman M.J., Maru D.M., Charnsangavej C., Loyer E.M., Wang H., Pathak P., et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010;28(15):2549–55. DOI: 10.1186/s12885-016-2998-2

86. Morioka D., Izumisawa Y., Yamaguchi K., Sato K., Komiyama S., Nakagawa K., et al. Surgical intervention for portal hypertension caused by oxaliplatin-based chemotherapy: A case report and a review of literature regarding radiological and/or surgical interventions for oxaliplatin-associated portal hypertension. Clin J Gastroenterol. 2020;13(5):799–805. DOI: 10.1007/s12328-020-01157-w

87. Lee W.M. Drug-induced acute liver failure. Clin Liver Dis. 2013;17(4):575–86. DOI: 10.1016/j.cld.2013.07.001

88. Tujios S., Stravitz R.T., Lee W.M. Management of acute liver failure: Update 2022. Semin Liver Dis. 2022;42(3):362–78. DOI: 10.1055/s-0042-1755274

89. Burt A.D., Ferrell L.D., Hübscher S.G., Portmann B.C. MacSween’s pathology of the liver. 6th ed. Churchill Livingstone, 2012:645–760.

90. Лазебник Л.Б., Голованова Е.В., Хлынова О.В., Алексеенко С.А., Арямкина О.Л., Бакулин И.Г. и др. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020;174(2):29–54. DOI: 10.31146/1682-8658-ecg-174-2-29-54

91. Calderon R.M., Cubeddu L.X., Goldberg R.B., Schiff E.R. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: A therapeutic dilemma. Mayo Clin Proc. 2010;85(4):349–56. DOI: 10.4065/mcp.2009.0365

92. Bessone F., Hernandez N., Tagle M., Arrese M., Parana R., Méndez-Sánchez N., et al. Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver. Ann Hepatol. 2021;24:100321. DOI: 10.1016/j.aohep.2021.100321

93. Ghabril M., Vuppalanchi R., Chalasani N. Drug-induced liver injury in patients with chronic liver disease. Liver Int. 2025;45(3):e70019. DOI: 10.1111/liv.70019

94. Chalasani N., Bonkovsky H.L., Fontana R., Lee W., Stolz A., Talwalkar J., et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology. 2015;148(7):1340– 52.e7. DOI: 10.1053/j.gastro.2015.03.006

95. Stephens C., Robles-Diaz M., Medina-Caliz I., Garcia-Cortes M., Ortega-Alonso A., Sanabria-Cabrera J., et al. Comprehensive analysis and insights gained from longterm experience of the Spanish DILI Registry. J Hepatol. 2021;75(1):86–97. DOI: 10.1016/j.jhep.2021.01.029

96. Fontana R.J., Watkins P.B., Bonkovsky H.L., Chalasani N., Davern T., Serrano J., et al.; DILIN Study Group. Drug-induced liver injury network (DILIN) prospective study: Rationale, design and conduct. Drug Saf. 2009;32(1):55–68. DOI: 10.2165/00002018-200932010-00005

97. De La Guerra R., Daniel T., Adewuyi O., Babich M. Drug-induced liver injury (DILI): A practical review. Pract Gastroenterol. 2024;(17):16–25. URL: https://practicalgastro.com/wp-content/uploads/2025/01/Babich-December-2024.pdf

98. Crabb D.W., Bataller R., Chalasani N.P., Kamath P.S., Lucey M., Mathurin P., et al.; NIAAA Alcoholic Hepatitis Consortia. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: Recommendation from the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology. 2016;150(4):785–90. DOI: 10.1053/j.gastro.2016.02.042

99. Ивашкин В.Т., Лазебник Л.Б., Голованова Е.В., Деева Т.А., Драпкина О.М., Еремина Е.Ю. и др. Алкогольная болезнь печени: клинические рекомендации. М.; 2024. URL: https://cr.minzdrav.gov.ru/preview-cr/711_2

100. Hayashi P.H., Rockey D.C., Fontana R.J., Tillmann H.L., Kaplowitz N., Barnhart H.X., et al.; Drug-Induced Liver Injury Network (DILIN) Investigators. Death and liver transplantation within 2 years of onset of druginduced liver injury. Hepatology. 2017;66(4):1275–85. DOI: 10.1002/hep.29283

101. Martinez-Cabriales S.A., Shear N.H., Gonzalez-More-no E.I. Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome. World J Clin Cases. 2019;7(6):705–16. DOI: 10.12998/wjcc.v7.i6.705

102. Kroshinsky D., Cardones A.R.G., Blumenthal K.G. Drug reaction with eosinophilia and systemic symptoms. N Engl J Med. 2024;391(23):2242–54. DOI: 10.1056/NEJMra2204547

103. Kano Y., Ishida T., Hirahara K., Shiohara T. Visceral involvements and long-term sequelae in druginduced hypersensitivity syndrome. Med Clin North Am. 2010;94(4):743–59. DOI: 10.1016/j.mcna.2010.03.004

104. Mockenhaupt M. Severe drug-induced skin reactions: Clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009;7(2):142–60. DOI: 10.1111/j.1610-0387.2008.06878.x

105. Fu S., Wu D., Jiang W., Li J., Long J., Jia C., et al. Molecular biomarkers in drug-induced liver injury: Challenges and future perspectives. Front Pharmacol. 2020;10:1667. DOI: 10.3389/fphar.2019.01667

106. Clarke J.I., Dear J.W., Antoine D.J. Recent advances in biomarkers and therapeutic interventions for hepatic drug safety — false dawn or new horizon? Expert Opin Drug Saf. 2016;15(5):625–34. DOI: 10.1517/14740338.2016.1160057

107. Senior J.R. Can rechallenge be done safely after mild or moderate drug-induced liver injury? Hepatology. 2016;63(3):691–3. DOI: 10.1002/hep.28353

108. Tajima S., Yamamoto N., Masuda S. Clinical prospects of biomarkers for the early detection and/or prediction of organ injury associated with pharmacotherapy. Biochem Pharmacol. 2019;170:113664. DOI: 10.1016/j.bcp.2019.113664

109. Gazzin S., Masutti F., Vitek L., Tiribelli C. The molecular basis of jaundice: An old symptom revisited. Liver Int. 2017;37(8):1094–102. DOI: 10.1111/liv.13351

110. Danan G., Benichou C. Causality assessment of adverse reactions to drugs. Part I: A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–30. DOI: 10.1016/0895-4356(93)90101-6

111. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11(2):272–6. DOI: 10.1016/0168-8278(90)90124-a

112. Benichou C., Danan G., Flahault A. Causality assessment of adverse reactions to drugs. Part II: An original model for validation of drug causality assessment methods: Case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331–6. DOI: 10.1016/0895-4356(93)90102-7

113. Agarwal V.K., McHutchison J.G., Hoofnagle J.H.; Drug-Induced Liver Injury Network. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010;8(5):463–70. DOI: 10.1016/j.cgh.2010.02.008

114. Сандлер Ю.Г., Винницкая Е.В., Райхельсон К.Л., Ивашкин К.В., Бацких С.Н., Александрова Е.Н. и др. Диагностика и лечение пациентов с аутоиммунным гепатитом (соглашение специалистов). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(6):100–19. DOI: 10.22416/1382-4376-2024-34-6-100-119

115. Tan E.M., Feltkamp T.E., Smolen J.S., Butcher B., Dawkins R., Fritzler M.J., et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 1997;40(9):1601–11. DOI: 10.1002/art.1780400909

116. Damoiseaux J., Andrade L.E.C., Carballo O.G., Conrad K., Francescantonio P.L.C., Fritzler M.J., et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: The International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879–89. DOI: 10.1136/annrheumdis-2018-214436

117. Mittal V., Muralee S., Tampi R.R. Valproic acid-induced hyperammonemia in the elderly: A review of the literature. Case Rep Med. 2009;2009:802121. DOI: 10.1155/2009/802121

118. Shakerdi L., Ryan A. Drug-induced hyperammonaemia. J Clin Pathol. 2023;76(8):501–9. DOI: 10.1136/jcp-2022-208644

119. Ahmad J., Reddy K.R., Tillmann H.L., Hayashi P.H., Chalasani N., Fontana R.J., et al. Importance of hepatitis C virus RNA testing in patients with suspected drug-induced liver injury. Dig Dis Sci. 2019;64(9):2645–52. DOI: 10.1007/s10620-019-05591-w

120. Grewal P., Ahmad J. Beware of HCV and HEV in patients with suspected drug-induced liver injury. Curr Hepatol Rep. 2018;17(3):270–5. DOI: 10.1007/s11901018-0410-1

121. Fontana R.J., Engle R.E., Hayashi P.H., Gu J., Kleiner D.E., Nguyen H., et al. Incidence of hepatitis E infection in American patients with suspected drug-induced liver injury is low and declining: The DILIN prospective study. Am J Gastroenterol. 2022;117(9):1462–70. DOI: 10.14309/ajg.0000000000001869

122. Davern T.J., Chalasani N., Fontana R.J., Hayashi P.H., Protiva P., Kleiner D.E., et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141(5):1665– 72. DOI: 10.1053/j.gastro.2011.07.051

123. European Association for the Study of the Liver. EASL-ERN Clinical Practice Guidelines on Wilson’s disease. J Hepatol. 2025;82(4):690–728. DOI: 10.1016/j.jhep.2024.11.007

124. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol. 2022;77(2):479–502. DOI: 10.1016/j.jhep.2022.03.033

125. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–72. DOI: 10.1016/j.jhep.2017.03.022

126. Hu S., Zhao F., Wang Q., Chen W.X. The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: A meta-analysis. Clin Chem Lab Med. 2014;52(11):1533–42. DOI: 10.1515/cclm-2013-0926

127. Balcerac A., Bihan K., Lebrun-Vignes B., Thabut D., Salem J.E., Weiss N. Drug-associated hyperammonaemia: A Bayesian analysis of the WHO Pharmacovigilance Database. Ann Intensive Care. 2022;12(1):55. DOI: 10.1186/s13613-022-01026-4

128. Надинская М.Ю., Маевская М.В., Бакулин И.Г., Бессонова Е.Н., Буеверов А.О., Жаркова М.С. и др. Диагностическое и прогностическое значение гипераммониемии у пациентов с циррозом печени, печеночной энцефалопатией и саркопенией (соглашение специалистов). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(1):85–100. DOI: 10.22416/13824376-2024-34-1-85-100

129. Vakrinou A., Murphy E., Sisodiya S.M., Vivekananda U., Balestrini S. Risk factors and outcome of hyperammonaemia in people with epilepsy. J Neurol. 2022;269(12):6395–405. DOI: 10.1007/s00415-022-11304-7

130. Meier C., Burns K., Manolikos C., Fatovich D., Bell D.A. Hyperammonaemia: Review of the pathophysiology, aetiology and investigation. Pathology. 2024;56(6):763–72. DOI: 10.1016/j.pathol.2024.06.002

131. Aitkenhead H. UK National audit of the measurement of ammonia. Ann Clin Biochem. 2023;60(2):117–25. DOI: 10.1177/00045632231152085

132. National Metabolic Biochemistry Network. Guidelines for the investigation of hyperammonaemia. 2023. URL: https://metbio.net/wp-content/uploads/MetBio-Guideline-PERE918546-10-12-2018.pdf

133. Ahmad J., Rossi S., Rodgers S.K., Ghabril M., Fontana R.J., Stolz A., et al. Sclerosing cholangitis-like changes on magnetic resonance cholangiography in patients with drug induced liver injury. Clin Gastroenterol Hepatol. 2019;17(4):789–90. DOI: 10.1016/j.cgh.2018.06.035

134. Grewal P., Ahmad J. Bile duct injury due to drug induced liver injury. Curr Hepatol Rep. 2019;18(3):269–73. DOI: 10.1007/s11901-019-00474-0

135. De Castro V.L., Moura E.G., Chaves D.M., Bernardo W.M., Matuguma S.E., Artifon E.L. Endoscopic ultrasound versus magnetic resonance cholangiopancreatography in suspected choledocholithiasis: A systematic review. Endosc Ultrasound. 2016;5(2):118–28. DOI: 10.4103/23039027.180476

136. Ahmed T., Ahmad J. Recent advances in the diagnosis of drug-induced liver injury. World J Hepatol. 2024;16(2):186–92. DOI: 10.4254/wjh.v16.i2.186

137. Larrey D., Meunier L., Valla D., Hillaire S., Hernandez-Gea V., Dutheil D., et al. Drug induced liver injury and vascular liver disease. Clin Res Hepatol Gastroenterol. 2020;44(4):471–9. DOI: 10.1016/j.clinre.2020.03.020

138. Del Carmen Manzano-Robleda M., Barranco-Fragoso B., Uribe M., Méndez-Sánchez N. Portal vein thrombosis: what is new? Ann Hepatol. 2015;14(1):20–7.

139. Park S.H., Choe J.Y., Kim S.K. Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate. Joint Bone Spine. 2010;77(6):588–92. DOI: 10.1016/j.jbspin.2010.02.024

140. Berends M.A., Snoek J., de Jong E.M., Van Krieken J.H., de Knegt R.J., van Oijen M.G., et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int. 2007;27(5):639–45. DOI: 10.1111/j.1478-3231.2007.01489.x

141. Crespo G., Fernández-Varo G., Mariño Z., Casals G., Miquel R., Martínez S.M., et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: A prospective study. J Hepatol. 2012;57(2):281–7. DOI: 10.1016/j.jhep.2012.03.016

142. Atallah E., Grove J.I., Crooks C., Burden-Teh E., Abhishek A., Moreea S., et al. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. J Hepatol. 2023;78(5):989–97. DOI: 10.1016/j.jhep.2022.12.034

143. Özkan S.G., Pata C., Şekuri A., Çınar Y., Özkan H.A. Transient elastography of liver: Could it be a guide for diagnosis and management strategy in hepatic veno-occlusive disease (sinusoidal obstruction syndrome)? Transfus Apher Sci. 2022;61(1):103370. DOI: 10.1016/j.transci.2022.103370

144. Ahmad J., Barnhart H.X., Bonacini M., Ghabril M., Hayashi P.H., Odin J.A., et al.; Drug-Induced Liver Injury Network. Value of liver biopsy in the diagnosis of drug-induced liver injury. J Hepatol. 2022;76(5):1070– 8. DOI: 10.1016/j.jhep.2021.12.043

145. Chalasani N.P., Hayashi P.H., Bonkovsky H.L., Navarro V.J., Lee W.M., Fontana R.J.; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–66. DOI: 10.1038/ajg.2014.131

146. Kleiner D.E. Role of liver biopsy in the management of idiosyncratic DILI. Liver Int. 2025;45(3):e16097. DOI: 10.1111/liv.16097

147. Danan G., Teschke R. RUCAM in drug and herb induced liver injury: The Update. Int J Mol Sci. 2015;17(1):14. DOI: 10.3390/ijms17010014

148. García-Cortés M., Stephens C., Lucena M.I., Fernández-Castañer A., Andrade R.J. Causality assessment methods in drug induced liver injury: Strengths and weaknesses. J Hepatol. 2011;55(3):683–91. DOI: 10.1016/j.jhep.2011.02.007

149. Teschke R., Wolff A., Frenzel C., Schwarzenboeck A., Schulze J., Eickhoff A. Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment. World J Hepatol. 2014;6(1):17–32. DOI: 10.4254/wjh.v6.i1.17

150. Teschke R., Eickhoff A., Schulze J. Drug- and herb-induced liver injury in clinical and translational hepatology: Causality assessment methods, quo vadis? J Clin Transl Hepatol. 2013;1(1):59–74. DOI: 10.14218/JCTH.2013.D002X

151. Hayashi P.H., Lucena M.I., Fontana R.J., Bjornsson E.S., Aithal G.P., Barnhart H., et al. A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology. 2022;76(1):18–31. DOI: 10.1002/hep.32327

152. Zhao X., Wang Y., Lai R., Wang X., Yu Y., Li M., et al. Validation of the revised electronic version of RUCAM for diagnosis of DILI in Chinese patients. Hepatol Commun. 2024;8(4):e0235. DOI: 10.1097/HC9.0000000000000235

153. Hayashi P.H., Fontana R.J. Clinical features, diagnosis and natural history of drug-induced liver injury. Semin Liver Dis. 2014;34(2):134–44. DOI: 10.1055/s-0034-1375955

154. Lucena M., Camargo R., Andrade R.J., Perez-Sanchez C.J., De LaCuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33(1):123–30. DOI: 10.1053/jhep.2001.20645

155. Takikawa H., Takamori Y., Kumagi T., Onji M., Watanabe M., Shibuya A., et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the international consensus meeting. Hepatol Res. 2003;27(3):192–5. DOI: 10.1016/s1386-6346(03)00232-8

156. Teschke R., Danan G. Worldwide use of RUCAM for causality assessment in 81,856 idiosyncratic DILI and 14,029 HILI cases published 1993 — mid 2020: A comprehensive analysis. Medicines (Basel). 2020;7(10):62. DOI: 10.3390/medicines7100062

157. Teschke R., Frenzel C., Schulze J., Eickhoff A. Herbal hepatotoxicity: Challenges and pitfalls of causality assessment methods. World J Gastroenterol. 2013;19(19):2864– 82. DOI: 10.3748/wjg.v19.i19.2864

158. Fontana R.J., Avigan M.I., Janssen H.L.A., Regev A., Mishra P., Gaggar A., et al. Liver safety assessment in clinical trials of new agents for chronic hepatitis B. J Viral Hep. 2020;27(2):96–109. DOI: 10.1111/jvh.13223

159. Regev A., Seeff L.B., Merz M., Ormarsdottir S., Aithal G.P., Gallivan J., et al. Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf. 2014;37(Suppl. 1):S47–56. DOI: 10.1007/s40264-014-0185-4

160. Rochon J., Protiva P., Seeff L.B., Fontana R.J., Liang-punsakul S., Watkins P.B., et al.; Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf causality assessment method for assessing causality in drug-induced liver injury. Hepatology. 2008;48(4):1175–83. DOI: 10.1002/hep.22442

161. Thakkar S., Li T., Liu Z., Wu L., Roberts R., Tong W. Drug-induced liver injury severity and toxicity (DILIst): Binary classification of 1279 drugs by human hepatotoxicity. Drug Discov Today. 2020;25(1):201–8. DOI: 10.1016/j.drudis.2019.09.022

162. Björnsson H.K., Björnsson E.S. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med. 2022;97:26–31. DOI: 10.1016/j.ejim.2021.10.035

163. Tillmann H.L., Suzuki A., Barnhart H.X., Serrano J., Rockey D.C. Tools for causality assessment in drug-induced liver disease. Curr Opin Gastroenterol. 2019;35(3):183–90. DOI: 10.1097/MOG.0000000000000526

164. Hayashi P.H., Barnhart H.X., Fontana R.J., Chalasani N., Davern T.J., Talwalkar J.A., et al. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the drug-induced liver injury network (DILIN). Liver Int. 2015;35(5):1623–32. DOI: 10.1111/liv.12540

165. Zeng G., Eslick G.D., Weltman M. Systematic review and meta-analysis: Comparing hepatocellular and cholestatic patterns of drug-induced liver injury. ILIVER. 2023;2(2):122–9. DOI: 10.1016/j.iliver.2023.05.002

166. Fontana R.J., Hayashi P.H., Gu J., Reddy K.R., Barnhart H., Watkins P.B., et al.; DILIN Network. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014;147(1):96–108.e4. DOI: 10.1053/j.gastro.2014.03.045

167. Ghabril M., Gu J., Yoder L., Corbito L., Ringel A., Beyer C.D., et al. Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected drug-induced liver injury. Gastroenterology. 2019;157(5):1245–52.e3. DOI: 10.1053/j.gastro.2019.07.006

168. Chalasani N., Fontana R.J., Bonkovsky H.L., Watkins P.B., Davern T., Serrano J., et al.; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924–34. DOI: 10.1053/j.gastro.2008.09.011

169. Björnsson E., Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481–9. DOI: 10.1002/hep.20800

170. Zimmerman H.J. Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver. New York: Appleton-Century-Crofts; 1978:351–5.

171. Jiménez M., Rodrigo L., Romero-Gomez M., Navarro J.M., Planas R., Costa J., et al.; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21. DOI: 10.1016/j.gastro.2005.05.006

172. Lo Re V. 3rd, Haynes K., Forde K.A., Goldberg D.S., Lewis J.D., Carbonari D.M., et al. Risk of acute liver failure in patients with drug-induced liver injury: Evaluation of Hy’s law and a new prognostic model. Clin Gastroenterol Hepatol. 2015;13(13):2360–8. DOI: 10.1016/j.cgh.2015.06.020

173. Robles-Diaz M., Lucena M.I., Kaplowitz N., Stephens C., Medina-Cáliz I., González-Jimenez A., et al.; Spanish DILI Registry; SLatinDILI Network; Safer and Faster Evidence-based Translation Consortium. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014;147(1):109–18.e5. DOI: 10.1053/j.gastro.2014.03.050

174. Wang Y., Zou C.L., Zhang J., Qiu L.X., Huang Y.F., Zhao X.Y., et al. Development and validation of a novel model to predict liver-related mortality in patients with idiosyncratic drug-induced liver injury. Hepatobiliary Pancreat Dis Int. 2023;22(6):584–93. DOI: 10.1016/j.hbpd.2023.06.002

175. Xiong X., Xu Q., Wang B. A retrospective study to evaluate Hy’s law, DrILTox ALF score, Robles-Diaz model, and a new logistic regression model for predicting acute liver failure in Chinese patients with drug-induced liver injury. Expert Opin Drug Saf. 2024;23(2):207–11. DOI: 10.1080/14740338.2023.2195624

176. Han L., Huang A., Chen J., Teng G., Sun Y., Chang B., et al. Clinical characteristics and prognosis of non-APAP drug-induced acute liver failure: A large multicenter cohort study. Hepatol Int. 2024;18(1):225–37. DOI: 10.1007/s12072-023-10541-w

177. Ghabril M., Gu J., Yoder L., Corbito L., Ringel A., Beyer C.D., et al. Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected drug-induced liver injury. Gastroenterology. 2019;157(5):1245–52.e3. DOI: 10.1053/j.gastro.2019.07.006

178. Wang Y., Zou C., Wee A., Liu J., Ma Z., Guo T., et al. Comparison of the prognostic models for mortality in idiosyncratic drug-induced liver injury. Hepatol Int. 2023;17(2):488–98. DOI: 10.1007/s12072-022-10405-9

179. McPhail M.J., Farne H., Senvar N., Wendon J.A., Bernal W. Ability of King’s College criteria and model for end-stage liver disease scores to predict mortality of patients with acute liver failure: A meta-analysis. Clin Gastroenterol Hepatol. 2016;14(4):516–25.e5. DOI: 10.1016/j.cgh.2015.10.007

180. Devarbhavi H., Patil M., Reddy V.V., Singh R., Joseph T., Ganga D. Drug-induced acute liver failure in children and adults: Results of a single-centre study of 128 patients. Liver Int. 2018;38(7):1322–9. DOI: 10.1111/liv.13662

181. Church R.J., Kullak-Ublick G.A., Aubrecht J., Bonkovsky H.L., Chalasani N., Fontana R.J., et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. Hepatology. 2019;69(2):760–73. DOI: 10.1002/hep.29802

182. Koch D.G., Tillman H., Durkalski V., Lee W.M., Reuben A. Development of a model to predict transplant-free survival of patients with acute liver failure. Clin Gastroenterol Hepatol. 2016;14(8):1199–206.e2. DOI: 10.1016/j.cgh.2016.03.046

183. Stravitz R.T., Lee W.M. Acute liver failure. Lancet. 2019;394(10201):869–81. DOI: 10.1016/S0140-6736(19)31894-X

184. O’Grady J.G., Alexander G.J., Hayllar K.M., Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439–45. DOI: 10.1016/0016-5085(89)90081-4

185. Panackel C., Raja K., Fawas M., Jacob M. Prognostic models in acute liver failure-historic evolution and newer updates “prognostic models in acute liver failure”. Best Pract Res Clin Gastroenterol. 2024;73:101957. DOI: 10.1016/j.bpg.2024.101957

186. McPhail M.J., Wendon J.A., Bernal W. Meta-analysis of performance of Kings’s College Hospital Criteria in prediction of outcome in non-paracetamol-induced acute liver failure. J Hepatol. 2010;53(3):492–9. DOI: 10.1016/j.jhep.2010.03.023

187. Лазебник Л.Б., Голованова Е.В., Хлынова О.В., Алексеенко С.А., Арямкина О.Л., Бакулин И.Г. и др. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020;174(2):29–54. DOI: 10.31146/1682-8658-ecg-174-2-29-54

188. M’Kada H., Perazzo H., Munteanu M., Ngo Y., Ramanujam N., Fautrel B., et al.; Drug Induced Liver Injury Groupe Hospitalier Pitié-Salpêtrière Group; Safer and Faster Evidence-based Translation Consortium. Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: A prospective pilot cohort study. PLoS ONE. 2012;7(8):e42418. DOI: 10.1371/journal.pone.0042418

189. Lewis J.H. ‘Hy’s law,’ the ‘Rezulin Rule,’ and other predictors of severe drug-induced hepatotoxicity: Putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf. 2006;15(4):221–9. DOI: 10.1002/pds.1209

190. Dara L., Liu Z.X., Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 2016;36(2):158–65. DOI: 10.1111/liv.12988

191. Pratt D.S., Kaplan M.M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342(17):1266–71. DOI: 10.1056/nejm200004273421707

192. Lewis J.H. The adaptive response (drug tolerance) helps to prevent drug-induced liver injury. Gastroenterol Hepatol (N Y). 2012;8(5):333–336.

193. Singhal R., Harrill A.H., Menguy-Vacheron F., Jayyosi Z., Benzerdjeb H., Watkins P.B. Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine. BMC Pharmacol Toxicol. 2014;15:42. DOI: 10.1186/2050-6511-15-42

194. FDA. Clinical white paper. 2000. URL: http://www.fda.gov/cder/livertox/clinical.pdf

195. Arora N., Goldhaber S.Z. Anticoagulants and transaminase elevation. Circulation. 2006;113(15):e698–702. DOI: 10.1161/CIRCULATIONAHA.105.603100

196. Lewis J.H., Khaldoyanidi S.K., Britten C.D., Wei A.H., Subklewe M. Clinical significance of transient asymptomatic elevations in aminotransferase (TAEAT) in oncology. Am J Clin Oncol. 2022;45(8):352–65. DOI: 10.1097/COC.0000000000000932

197. FDA. Guidance for industry: Drug-induced liver injury: premarketing clinical evaluation. 2009. URL: https://www.fda.gov/media/116737/download

198. Ткаченко П.Е., Маевская М.В., Ивашкин В.Т. Гепатотоксичность. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли. 2024;14(3s2):83–96. DOI: 10.18027/2224-5057-2024-14-3s2-2-05

199. Viganò M., La Milia M., Grassini M.V., Pugliese N., De Giorgio M., Fagiuoli S. Hepatotoxicity of small molecule protein kinase inhibitors for cancer. Cancers (Basel). 2023;15(6):1766. DOI: 10.3390/cancers15061766

200. Минздрав РФ. Государственный реестр лекарственных средств (ГРЛС). URL: http://grls.rosminzdrav.ru

201. Минздрав РФ. Рубрикатор клинических рекомендаций. URL: https://cr.minzdrav.gov.ru

202. Cunningham M., Gupta R., Butler M. Checkpoint inhibitor hepatotoxicity: Pathogenesis and management. Hepatology. 2024;79(1):198–212. DOI: 10.1097/HEP.0000000000000045

203. Peeraphatdit T.B., Wang J., Odenwald M.A., Hu S., Hart J., Charlton M.R. Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation. Hepatology. 2020;72(1):315–29. DOI: 10.1002/hep.31227

204. Huffman B.M., Kottschade L.A., Kamath P.S., Markovic S.N. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: Natural progression and management. Am J Clin Oncol. 2018;41(8):760–5. DOI: 10.1097/COC.0000000000000374

205. Riveiro-Barciela M., Barreira-Díaz A., Callejo-Pérez A., Muñoz-Couselo E., Díaz-Mejía N., Díaz-González Á., et al. Retreatment with immune checkpoint inhibitors after a severe immune-related hepatitis: Results from a prospective multicenter study. Clin Gastroenterol Hepatol. 2023;21(3):732–40. DOI: 10.1016/j.cgh.2022.03.050

206. Licata A., Minissale M.G., Stankevičiūtė S., Sanabria-Cabrera J., Lucena M.I., Andrade R.J., et al. N-acetylcysteine for preventing acetaminophen-induced liver injury: A comprehensive review. Front Pharmacol. 2022;13:828565. DOI: 10.3389/fphar.2022.828565

207. Stine J.G., Lewis J.H. Current and future directions in the treatment and prevention of drug-induced liver injury: A systematic review. Expert Rev Gastroenterol Hepatol. 2016;10(4):517–36. DOI: 10.1586/17474124.2016.1127756

208. Woodhead J.L., Howell B.A., Yang Y., Harrill A.H., Clewell H.J. 3rd, Andersen M.E., et al. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther. 2012;342(2):529–40. DOI: 10.1124/jpet.112.192930

209. Chen Y., Johansson E., Yang Y., Miller M.L., Shen D., Orlicky D.J., et al. Oral N-acetylcysteine rescues lethality of hepatocyte-specific Gclc-knockout mice, providing a model for hepatic cirrhosis. J Hepatol. 2010;53(6):1085– 94. DOI: 10.1016/j.jhep.2010.05.028

210. González R., Ferrín G., Hidalgo A.B., Ranchal I., López-Cillero P., Santos-Gónzalez M., et al. N-acetylcysteine, coenzyme Q10 and superoxide dismutase mimetic prevent mitochondrial cell dysfunction and cell death induced by d-galactosamine in primary culture of human hepatocytes. Chem Biol Interact. 2009;181(1):95–106. DOI: 10.1016/j.cbi.2009.06.003

211. Jin X., Wang L., Wu H.S., Zhang L., Wang C.Y., Tian Y., et al. N-acetylcysteine inhibits activation of tolllike receptor 2 and 4 gene expression in the liver and lung after partial hepatic ischemia-reperfusion injury in mice. Hepatobiliary Pancreat Dis Int. 2007;6(3):284–9.

212. Popescu M., Bratu A., Agapie M., Borjog T., Jafal M., Sima R.M., et al. The use and potential benefits of N-acetylcysteine in non-acetaminophen acute liver failure: An etiology-based review. Biomedicines. 2024;12(3):676. DOI: 10.3390/biomedicines12030676

213. Chiew A.L., Reith D., Pomerleau A., Wong A., Isoardi K.Z., Soderstrom J., Buckley N.A. Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand. Med J Aust. 2020;212(4):175–83. DOI: 10.5694/mja2.50428

214. Green J.L., Heard K.J., Reynolds K.M., Albert D. Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: A systematic review and meta-analysis. West J Emerg Med. 2013;14(3):218–26. DOI: 10.5811/westjem.2012.4.6885

215. Avigan M.I. DILI and drug development: A regulatory perspective. Semin Liver Dis. 2014;34(2):215–26. DOI: 10.1055/s-0034-1375961

216. Hendrickson R.G. What is the most appropriate dose of N-acetylcysteine after massive acetaminophen overdose? Clin Toxicol (Phila). 2019;57(8):686–91. DOI: 10.1080/15563650.2019.1579914

217. Virmani M.A., Cirulli M. The role of l-carnitine in mitochondria, prevention of metabolic inflexibility and disease initiation. Int J Mol Sci. 2022;23(5):2717. DOI: 10.3390/ijms23052717

218. Perrott J., Murphy N.G., Zed P.J. L-carnitine for acute valproic acid overdose: A systematic review of published cases. Ann Pharmacother. 2010;44(7–8):1287–93. DOI: 10.1345/aph.1P135

219. Meijer R., Vivekananda U., Balestrini S., Walker M., Lachmann R., Haeberle J., et al. Ammonia: What adult neurologists need to know. Pract Neurol. 2020;practneurol-2020-002654. DOI: 10.1136/practneurol-2020-002654

220. Russell S. Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr. 2007;19(2):206– 10. DOI: 10.1097/MOP.0b013e32805e879a

221. Bohan T.P., Helton E., McDonald I., König S., Gazitt S., Sugimoto T., et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology. 2001;56(10):1405–9. DOI: 10.1212/wnl.56.10.1405

222. Schulte R., Hinson A., Huynh V., Breese E.H., Pierro J., Rotz S., et al. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. Cancer Med. 2021;10(21):7551– 60. DOI: 10.1002/cam4.4281

223. Blackman A., Boutin A., Shimanovsky A., Baker W.J., Forcello N. Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature. J Oncol Pharm Pract. 2018;24(5):393–7. DOI: 10.1177/1078155217710714

224. Bessone F., Hillotte G.L., Ahumada N., Jaureguizahar F., Medeot A.C., Roma M.G. UDCA for drug-induced liver disease: Clinical and pathophysiological basis. Semin Liver Dis. 2024;44(1):1–22. DOI: 10.1055/s-0044-1779520

225. Bessone F., Hillotte G.L., Tamagnone N., Arnedillo D., Roma M.G. Ursodeoxycholic acid for the management of drug-induced liver injury: Role of hepatoprotective and anti-cholestatic mechanisms. J Clin Transl Hepatol. 2025;13(2):162–8. DOI: 10.14218/JCTH.2024.00325

226. Devarbhavi H., Aithal G., Treeprasertsuk S., Takikawa H., Mao Y., Shasthry S.M., et al.; Asia Pacific Association of Study of Liver. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int. 2021;15(2):258–82. DOI: 10.1007/s12072-021-10144-3

227. Robles-Díaz M., Nezic L., Vujic-Aleksic V., Björnsson E.S. Role of ursodeoxycholic acid in treating and preventing idiosyncratic drug-induced liver injury. A systematic review. Front Pharmacol. 2021;12:744488. DOI: 10.3389/fphar.2021.744488

228. Wree A., Dechêne A., Herzer K., Hilgard P., Syn W.K., Gerken G., et al. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. Digestion. 2011;84(1):54–9. DOI: 10.1159/000322298

229. Stepanov Y., Yagmur V., Melanich S., Popok D. Efficacy of ursodeoxycholic acid in the treatment of COVID-19 infection and drug-induced liver damage. Gastroenterology (Ukraine). 2021;55(1):14–20. DOI: 10.22141/23082097.55.1.2021.229431

230. Lang S.M., Ortmann J., Rostig S., Schiffl H. Ursodeoxycholic acid attenuates hepatotoxicity of multidrug treatment of mycobacterial infections: A prospective pilot study. Int J Mycobacteriol. 2019;8(1):89–92. DOI: 10.4103/ijmy.ijmy_159_18

231. Максимова Е.В., Кляритская И.Л. Гепатотоксичность у пациентов ревматологического профиля: особенности течения, возможности коррекции. Крымский терапевтический журнал. 2015;1:58–64.

232. Singh C., Bishop P., Willson R. Extreme hyperbilirubinemia associated with the use of anabolic steroids, health/nutritional supplements, and ethanol: Response to ursodeoxycholic acid treatment. Am J Gastroenterol. 1996;91(4):783–5.

233. Cicognani C., Malavolti M., Morselli-Labate A.M., Sama C., Barbara L. Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis. Dig Dis Sci. 1996;41(11):2219–21. DOI: 10.1007/BF02071403

234. Katsinelos P., Vasiliadis T., Xiarchos P., Patakiouta F., Christodoulou K., Pilpilidis I., et al. Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: report of two cases. Eur J Gastroenterol Hepatol. 2000;12(3):365–8. DOI: 10.1097/00042737-200012030-00017

235. Sánchez-Osorio M., Duarte-Rojo A., Martínez-Benítez B., Torre A., Uribe M. Anabolic-androgenic steroids and liver injury. Liver Int. 2008;28(2):278–82. DOI: 10.1111/j.1478-3231.2007.01579.x

236. Shah A., Bassi N., Parihar S., Mittal I., Yadav D.P., Kumar V., et al. Steroid-responsive intractable pruritus in drug-induced liver injury: A case series. J Clin Trans Res. 2024;10(1):25–32. DOI: 10.36922/jctr.00104

237. Mato J.M., Martínez-Chantar M.L., Lu S.C. S-adenosylmethionine metabolism and liver disease. Ann Hepatol. 2013;12(2):183–9. DOI: 10.1016/S1665-2681(19)31355-9

238. Приходько В.А., Оковитый С.В. Хемопревентивный и противоопухолевый потенциал адеметионина при хронических заболеваниях печени. Терапия. 2024;10(3):125– 36. DOI: 10.18565/therapy.2024.3.125-136

239. Noureddin M., Sander-Struckmeier S., Mato J.M. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. World J Hepatol. 2020;12(2):46–63. DOI: 10.4254/wjh.v12.i2.46

240. Chinese Medical Association Tuberculosis Branch. [Guidelines for diagnosis and management of drug-induced liver injury caused by anti-tuberculosis drugs (2024 version)]. Zhonghua Jie He He Hu Xi Za Zhi. 2024;47(11):1069–90. (In Chinese). DOI: 10.3760/cma.j.cn112147-20240614-00338

241. Снеговой А.В., Ларионова В.Б., Зейналова П.А., Манзюк Л.В., Крейнина Ю.М., Кагония Л.М. Окончательные результаты проспективной многоцентровой программы p12-717 (применение Гептрала при хронической болезни печени, обусловленной лекарственноиндуцированным поражением печени вследствие химиотерапии). Вестник РОНЦ им. Н.Н. Блохина РАМН. 2016;27(2):142–56.

242. Vincenzi B., Russo A., Terenzio A., Galvano A., Santini D., Vorini F., et al. The use of SAMe in chemotherapy-induced liver injury. Crit Rev Oncol Hematol. 2018;130:70–7. DOI: 10.1016/j.critrevonc.2018.06.019

243. Ларионова В.Б., Снеговой А.В. Возможности коррекции лекарственной печеночной токсичности при лечении больных с опухолями системы крови. Онкогематология. 2020;15(4):65–81. DOI: 10.17650/1818-8346-2020-15-4-65-81

244. Снеговой А.В., Манзюк Л.В. Эффективность Гептрала в лечении печеночной токсичности, обусловленной цитостатической химиотерапией. Опухоли женской репродуктивной системы. 2010;2:47–52. DOI: 10.17650/1994-4098-2010-0-2-47-52

245. Perlamutrov Y., Bakulev A., Korsunskaya I., Orlov E., Bolotnikova N. Ademetionine in treatment of drug induced liver injury: An observational study in Russian patients, receiving immunosuppressive therapy for psoriasis. Int J Pharm Sci Res. 2014;5(12):5163–9. DOI: 10.13040/IJPSR.0975-8232.5(12).5163-69

246. Силивончик Н.Н., Адаменко Е.И., Богуш Л.С. Адеметионин: физиологические эффектыи применение в лечении заболеваний печени. Международные обзоры: клиническая практика и здоровье, 2017;(2):33–49.

247. Суханов Д.С., Павлова М.В., Яблонский П.К., Виноградова Т.И. Сравнительная эффективность клинического применения реамберина, ремаксола и адеметионина у больных туберкулезом органов дыхания с лекарственными поражениями печени. Антибиотики и химиотерапия. 2013;58(1–2):13–8.

248. Суханов Д.С. Антиоксидантные свойства ремаксола, реамберина и адеметионина при лекарственных поражениях печени у больных на фоне противотуберкулезной терапии. Экспериментальная и клиническая фармакология. 2013;76(4):45–8.

249. Liu Y.H., Da R.F., Xu H.B., Jiang Y., Xie H.P. Therapeutic efficacy of polyene phosphatidylcholine in patients with antituberculosis agents-induced liver injury. Journal of Practical Hepatology (Shiyong Ganzangbing Zazhi). 2021; 24(02):228–31. DOI: 10.3969/j.issn.1672-5069.2021.02.020

250. Osipova D., Kokoreva K., Lazebnik L., Golovanova E., Pavlov C., Dukhanin A., et al. Regression of liver steatosis following phosphatidylcholine administration: A review of molecular and metabolic pathways involved. Front Pharmacol. 2022;13:797923. DOI: 10.3389/fphar.2022.797923

251. Lei P., Cao L., Zhang H., Fu J., Wei X., Zhou F., et al. Polyene phosphatidylcholine enhances the therapeutic response of oxaliplatin in gastric cancer through Nrf2/HMOX1 mediated ferroptosis. Transl Oncol. 2024;43:101911. DOI: 10.1016/j.tranon.2024.101911

252. Lei X., Zhang J., Xu Q., Li J., Qian Y., Zhang J., et al. Exploring the efficacy and safety of polyene phosphatidylcholine for treatment of drug-induced liver injury using the Roussel Uclaf causality assessment method: a propensity score matching comparison. J Int Med Res. 2021;49(8):3000605211039810. DOI: 10.1177/03000605211039810

253. Li C., Yang X., Quan Y., Wu A., Wang Y. Network meta-analysis of different liver protective drugs in the treatment of drug-induced liver injury. Medicine (Baltimore). 2023;102(50):e36538. DOI: 10.1097/MD.0000000000036538

254. Пальгова Л.К., Борисова И.В., Жесткова Н.В., Тарасова М.А. Применение эссенциальных фосфолипидов в лечении лекарственных поражений печени при беременности. Журнал акушерства и женских болезней. 2017;66(2):14–23. DOI: 10.17816/JOWD66214-23

255. Алыева А.А., Никитин И.Г., Архипов А.В. Сопроводительная терапия острого лекарственного повреждения печени на фоне химиотерапевтического лечения у пациенток с раком молочной железы. Лечебное дело. 2018;2:74–85. DOI: 10.24411/2071-5315-2018-12005

256. Денисова Е.В., Дворянкова Е.В., Плиева К.Т., Соболев В.В., Корсунская И.М. Патологии гепатобилиарной системы у больных псориазом. Эффективная фармакотерапия. 2018;21:18–23. .

257. Новикова Т.И., Новиков В.С. Опыт применения препарата «Фосфоглив» в терапии поражения печени на фоне химиотерапии легких. Материалы конференции «Туберкулез и болезни легких», IX Cъезд фтизиатров России. 2011:768.

258. Оковитый С.В., Никитин И.Г. Анализ безопасности применения глицирризиновой кислоты у человека. Эффективная фармакотерапия. 2023;19(8):92–103. DOI: 10.33978/23073586-2023-19-8-92-103

259. Butterworth R.F., Canbay A. Hepatoprotection by L-ornithine L-aspartate in non-alcoholic fatty liver disease. Dig Dis. 2019;37(1):63–8. DOI: 10.1159/000491429

260. Canbay A., Sowa J.P. L-ornithine L-aspartate (LOLA) as a novel approach for therapy of non-alcoholic fatty liver disease. Drugs. 2019;79(Suppl. 1):39–44. DOI: 10.1007/ s40265-018-1020-5

261. Максимова Е.В., Кляритская И.Л. Печеночная энцефалопатия, диагностика, дифференциальная диагностика и терапия при помощи орнитина. Consilium Medicum. 2018;20(12):110–6. DOI: 10.26442/20751753.2018.12.000019

262. Ларионова В.Б., Горожанская Э.Г. Перспективы применения Гепа-Мерц (L-орнитин-L-аспартат) для профилактики и лечения лекарственного поражения печени. Эффективная фармакотерапия. 2009;23:6–15.

263. Оковитый С.В., Надинская М.Ю., Маевская М.В., Гладков О.А., Васенина Е.Е., Гречишникова В.Р. и др. Резолюция экспертного совета «Орнитин в онкологической практике». Медицинский совет. 2025;8:8–16. DOI: 10.21518/ms2025-237

264. Бриштель М.В. Применение препарата L-орнитина — L-аспартат (Гепа-Мерц) для терапии гепатотоксичности при лечении злокачественных новообразований. Медицинские новости. 2024;3:68–70.

265. Скрыпник И.Н., Маслова А.С., Скрыпник Р.И. Влияние L-орнитина-L-аспартата на проявления минимальной печеночной энцефалопатии в динамике цитостатической терапии. Современная гастроэнтерология. 2018;6:29– 34. DOI: 10.30978/MG-2018-6-29

266. Ивашкин В.Т., Драпкина О.М., Маевская М.В., Жаркова М.С., Гречишникова В.Р. и др. Цирроз и фиброз печени: клинические рекомендации. М.; 2025. URL: https://cr.minzdrav.gov.ru/preview-cr/715_2

267. Оковитый С.В., Радько С.В. Митохондриальная дисфункция в патогенезе различных поражений печени. Доктор.Ру. 2015;12(113):30–3.

268. Ильченко Л.Ю., Оковитый С.В. Ремаксол: механизмы действия и применение в клинической практике. Ч. 2. Архивъ внутренней медицины. 2016;6(3):8–18. DOI: 10.20514/2226-6704-2016-6-3-8-18

269. Оковитый С.В., Приходько В.А., Безбородкина Н.Н., Кудрявцев Б.Н. Гепатопротекторы: руководство для врачей. 2-е изд. М.: ГЭОТАР-Медиа, 2022.

270. Коломиец В.М., Коваленко А.Л., Таликова Е.В. Эффективность использования ремаксола в терапии сопровождения при запущенном туберкулезе. Антибиотики и химиотерапия. 2019;64(5–6):44–8. DOI: 10.24411/0235-2990-2019-100030

271. Красова Е.К., Ковалева Е.А., Оковитый С.В. Оценка эффективности и безопасности сукцинатов при лекарственных поражениях печени: систематический обзор. Медицинский совет. 2025;19(15):102–17. DOI: 10.21518/ms2025-325

272. Коломиец В.М., Коваленко А.Л., Петров А.Ю., Павленко Е.П., Таликова Е.В. Некоторые особенности терапии современного коморбидного туберкулеза. Антибиотики и химиотерапия. 2022;67(11–12):46– 50. DOI: 10.37489/0235-2990-2022-67-11-12-46-50

273. Коломиец В.М., Коваленко А.Л., Петров А.Ю., Павленко Е.П., Таликова Е.В. Эффективность сукцинатсодержащего препарата в терапии сопровождения при лечении коморбидного туберкулеза в условиях пенитенциарного учреждения. Антибиотики и химиотерапия. 2020;65(9–10):32–6. DOI: 10.37489/0235-2990-2020-65-9-10-32-36

274. Мордык А.В., Иванова О.Г., Нагибина Л.А., Ситникова С.В., Марьехина О.А. Лекарственные поражения печени и их лечение в клинике туберкулеза. Туберкулез и болезни легких. 2015;9:47–53.

275. Шевырева Е.В., Иванов А.К., Суханов Д.С., Мурзина А.А. Гепатопротекторная терапия ремаксолом у больных туберкулезом и ВИЧ-инфекцией в дневном стационаре противотуберкулезного диспансера. Антибиотики и химиотерапия. 2012;57(7–8):31–7.

276. Сас Е.И., Гриневич В.Б. Многокомпонентные инфузионные гепатопротекторы при лекарственном поражении печени. Медицинский совет. 2019;3:84–8. DOI: 10.21518/2079-701X-2019-3-84-88

277. Павлов А.И., Балабанов А.С., Бакирова В.Э., Каракозов А.Г., Андреев Д.Н., Молодова А.И. и др. Оценка эффективности гепатопротектора в лечении токсического (лекарственного) поражения печени. Медицинский совет. 2025;19(8):126–33. DOI: 10.21518/ms2025-232

278. Конопацкова О.М., Аверьянова С.В. Применение Ремаксола при полихимиотерапии у больных раком молочной железы. Онкология. Журнал им. П.А. Герцена. 2015;4(6):35–7.

279. Бондаренко Д.А., Смирнов Д.В., Симонова Н.В., Доровских В.А. Опыт применения ремаксола при полихимиотерапии рака яичников. Онкология. Журнал им. П.А. Герцена. 2020;9(6):39–44. DOI: 10.17116/onkolog2020906139

280. Черенков В.Г., Петров А.Б., Васильева Т.М., Строженков М.М. Возможности ремаксола для профилактики токсических гепатитов при химиотерапии онкологических больных. Вопросы онкологии. 2013;59(3):369–74.

281. Дрогомирецкая Е.И., Трашков А.П., Балашов В.К., Бобраков М.А., Ерохина Е.А., Круглов А.Н. и др. Экспериментальный и клинический опыт применения Ремаксола как препарата сопровождения при противоопухолевом лечении. Эффективная фармакотерапия. 2018;(25):34–41.

282. Конопацкова О.М., Аверьянова С.В. Сопроводительная терапия при проведении полихимиотерапии колоректального рака. Онкология. Журнал им. П.А. Герцена. 2016;5(1):42–6.

283. Безбородова О.А., Немцова Е.Р., Венедиктова Ю.Б., Якубовская Р.И., Александрова Л.Н., Коваленко А.Л. Экспериментальное изучение ремаксола как препарата поддерживающей терапии при традиционной и высокодозной химиотерапии опухоли. Экспериментальная и клиническая фармакология. 2013;76(5):18–22. DOI: 10.30906/0869-2092-2013-76-5-18-22

284. Филиппова Н.В., Барыльник Ю.Б., Шульдяков А.А. Применение ремаксола в качестве гепатопротектора при длительной психофармакотерапии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(4):43–6. DOI: 10.17116/jnevro201911901143

285. Zhao T., Mao L., Yu Z., Hui Y., Feng H., Wang X., et al. Therapeutic potential of bicyclol in liver diseases: Lessons from a synthetic drug based on herbal derivative in traditional Chinese medicine. Int Immunopharmacol. 2021;91:107308. DOI: 10.1016/j.intimp.2020.107308

286. Yao X.M., Wang B.L., Gu Y., Li Y. Effects of bicyclol on the activity and expression of CYP450 enzymes of rats after partial hepatectomy. Yao Xue Xue Bao. 2011;46(6):656–63.

287. Bao X., Liu G., Wang Y., Nie H., Zhao X., Qin Y., et al. Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/ AKT and Ras/Raf/MEK/ERK pathways. BMC Cancer. 2016;16(1):742. DOI: 10.1186/s12885-016-2767-2

288. Liu X., Zhao M., Mi J., Chen H., Sheng L., Li Y. Protective effect of bicyclol on anti-tuberculosis drug induced liver injury in rats. Molecules. 2017;22(4):524. DOI: 10.3390/molecules22040524

289. Chen F., Zou H., Zhang P., Yan Y. Investigation on the in vitro metabolism of bicyclol using liver microsomes, hepatocytes and human recombinant cytochrome P450 enzymes. Xenobiotica. 2023;53(4):231–40. DOI: 10.1080/00498254.2023.2222385

290. Li X., Zhou J., Chen S., Guan M., Wang Y., Zhao L., et al. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res. 2014;42(4):906–14. DOI: 10.1177/0300060514527058

291. Naiqiong W., Liansheng W., Zhanying H., Yuanlin G., Chenggang Z., Ying G., et al. A multicenter and randomized controlled trial of bicyclol in the treatment of statin-induced liver injury. Med Sci Monit. 2017;23:5760–6. DOI: 10.12659/msm.904090

292. Niu H., Sanabria-Cabrera J., Alvarez-Alvarez I., Robles-Diaz M., Stankevičiūtė S., Aithal G.P., et al. Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. Pharmacol Res. 2021;164:105404. DOI: 10.1016/j.phrs.2020.105404

293. Chu N.H., Li L., Zhang X., Gu J., Du Y.D., Cai C., et al. Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease. Int J Tuberc Lung Dis. 2015;19(4):475–80. DOI: 10.5588/ijtld.14.0579

294. Du Y., Gu J., Yang Y., Chen Y., Wang Y., Mei Z., et al. Efficacy and safety of bicyclol for treating patients with antituberculosis drug-induced liver injury. Int J Tuberc Lung Dis. 2024;28(1):6–12. DOI: 10.5588/ijtld.23.0038

295. Wang X., Zhao S., Wang Q., Ma A. Protective effect of bicyclol on anti-tuberculosis drug-induced hepatotoxicity: A meta-analysis. Chin J Dis Control Prev. 2018;22(4):390–5. DOI: 10.16462/j.cnki.zhjbkz.2018.04.016

296. Tang J., Gu J., Chu N., Chen Y., Wang Y., Xue D., et al. Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: A multicenter, randomized, phase II trial. Liver Int. 2022;42(8):1803–13. DOI: 10.1111/liv.15290

297. Приходько В.А., Оковитый С.В. Возможности применения морфолиния тиазотата в качестве средства фармакотерапии состояний гепатокардиального континуума. Медицинский совет. 2024;18(23):94–103. DOI: 10.21518/ms2024-517

298. Bielenichev I.F., Maslennikov S.O., Dobrelia N.V., Khromov O.S., Holovakha M.L., Ryzhenko V.P., et al. The role of adipose tissue cell elements in the regulation of the nitroxidergic system and possible ways of pharmacological modulation. Mod Med Technol. 2024;16(2):122–31. DOI: 10.14739/mmt.2024.2.299862.14

299. Popazova O., Belenichev I., Bukhtiyarova N., Ryzhenko V., Oksenych V., Kamyshnyi A. Cardioprotective activity of pharmacological agents affecting NO production and bioavailability in the early postnatal period after intrauterine hypoxia in rats. Biomedicines. 2023;11(10):2854. DOI: 10.3390/biomedicines11102854

300. Топчий Н.В., Топорков А.С. Возможности применения Тиотриазолина в качестве средства метаболической терапии. РМЖ. 2015;23(15):890–4.

301. Маевская М.В., Оковитый С.В., Приходько В.А. Морфолиния тиазотат в лечении заболеваний печени и сочетанном поражении печени и сердечно-сосудистой системы (описательный обзор). Медицинский совет. 2025;8:64–71. DOI: 10.21518/ms2025-211

302. Кольцов А.В., Тыренко В.В. Опыт лечения сердечной недостаточности как проявления кардиотоксичности химиотерапии у онкологических пациентов. Эффективная фармакотерапия. 2023;19(33):18–22. DOI: 10.33978/2307-3586-2023-19-33-18-22

303. Гречканев Г.О., Чурикова М.С. Влияние препарата Тиотриазолин® на функциональную активность печени, перекисное окисление липидов и антиоксидантную систему крови у пациенток с воспалительными заболеваниями органов малого таза, длительно получающих антибактериальную терапию. Поликлиника. 2012;(4–1): 67–70.

304. Шовкун Л.А., Кампос Е.Д., Романцева Н.Э. Гепатопротекторные и антиоксидантные эффекты тиотриазолина при лечении больных туберкулезом легких. Журнал фундаментальной медицины и биологии. 2013;2:72–8.

305. Оковитый С.В., Райхельсон К.Л., Приходько В.А. Комбинированная гепатопротекторная фармакотерапия заболеваний печени. Экспериментальная и клиническая гастроэнтерология. 2022;7:5–20. DOI: 10.31146/1682-8658-ecg-203-7-5-20

306. Скрипник І.М., Маслова Г.С. Особливості профілактики уражень печінки у хворих на гостру лімфобластну лейкемію у поєднанні з ожирінням. Украинский терапевтический журнал. 2020;2:14–9. DOI: 10.30978/UTJ2020-2-14

307. Ye Y.J., Yu J.P., Xu Y.M., Wang H., Xie Q. The treatment effect of ursodeoxycholic acid combined with S-adenosyl-L-methionine on drug-induced cholestatic liver injury. Chin Hepatol. 2017;22(12):1090–3. DOI: 10.14000/j.cnki.issn.1008-1704.2017.12.007

308. Wree A., Dechêne A., Herzer K., Hilgard P., Syn W.K., Gerken G., et al. Steroid and ursodeoxycholic acid combination therapy in severe drug-induced liver injury. Digestion. 2011;84(1):54–9. DOI: 10.1159/000322298

309. Onishi S., Tajika M., Bando H., Matsubara Y., Hosoda W., Muro K., et al. Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: A case report. J Med Case Rep. 2020;14(1):230. DOI: 10.1186/s13256-020-02541-3

310. Wu J., Xie L.X., Xiu J. Short-term efficacy of polyene phosphatidylcholine and bicyclol combination in treatment of gastric cancer patients with chemotherapy-induced liver injury. J Prac Hepatol. 2020;23(5):666–9. DOI: 10.3969/j.issn.1672-5069.2020.05.016

311. Wang H.X., Zhu Q.J., Zhang Y.J., Mao C. Efficacy of acetylcysteine combined with magnesium isoglycyrrhizinate in treatment of patients with drug-induced liver injuries. J Prac Hepatol. 2020;23(2):227–30. DOI: 10.3969/j.issn.1672-5069.2020.02.020

312. Bordbar M., Shakibazad N., Fattahi M., Haghpanah S., Honar N. Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia. Turk J Gastroenterol. 2018;29(2):203–9. DOI: 10.5152/tjg.2018.17521

313. Stirnimann G., Robles-Díaz M. Role of corticosteroids in drug-induced liver injury. A systematic review. Front Pharmacol. 2022;13:820724. DOI: 10.3389/fphar.2022.820724

314. European Association for the Study of the Liver. EASL clinical practice guidelines: Autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004. DOI: 10.1016/j.jhep.2015.06.030

315. Björnsson E.S., Medina-Cádiz I., Andrade R.J., Lucena M.L. Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports. Hepatol Commun. 2022;6(8):1895–909. DOI: 10.1002/hep4.1959

316. Wilkenfeld S.R., Lin C., Frigo D.E. Communication between genomic and non-genomic signaling events coordinate steroid hormone actions. Steroids. 2018;133:2–7. DOI: 10.1016/j.steroids.2017.11.005

317. Panettieri R.A., Schaafsma D., Amrani Y., Koziol-White C., Ostrom R., Tliba O. Non-genomic effects of glucocorticoids: An updated view. Trends Pharmacol Sci. 2019;40(1):38–49. DOI: 10.1016/j.tips.2018.11.002

318. Karkhanis J., Verna E.C., Chang M.S., Stravitz R.T., Schilsky M., Lee W.M., et al. Steroid use in acute liver failure. Hepatology. 2014;59(2):612–21. DOI: 10.1002/hep.26678

319. Song F.J., Liu H.L., Sun Y., Xu T.J., Li D.Z., Wang H.B., et al. Prednisolone therapy accelerates recovery of severe drug-induced liver injury: A prospective, randomized controlled study. ILIVER. 2023;2(3):156–62. DOI: 10.1016/j.iliver.2023.06.001

320. Niu H., Ma J., Medina-Caliz I., Robles-Diaz M., Bonilla-Toyos E., Ghabril M., et al. Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: An international, multicentre, propensity score-matched analysis. Aliment Pharmacol Ther. 2023;57(8):886–96. DOI: 10.1111/apt.17373

321. Björnsson E.S., Vucic V., Stirnimann G., Robles-Díaz M. Role of corticosteroids in drug-induced liver injury. A systematic review. Front Pharmacol. 2022;13:820724. DOI: 10.3389/fphar.2022.820724

322. Hu P.F., Wang P.Q., Chen H., Hu X.F., Xie Q.P., Shi J., et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. J Dig Dis. 2016;17(9):618–27. DOI: 10.1111/1751-2980.12383

323. Mack C.L., Adams D., Assis D.N., Kerkar N., Manns M.P., Mayo M.J., et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671–722. DOI: 10.1002/hep.31065

324. Wang Q., Huang A., Wang J.B., Zou Z. Chronic drug-induced liver injury: Updates and future challenges. Front Pharmacol. 2021;12:627133. DOI: 10.3389/fphar.2021.627133

325. Schneider B.J., Naidoo J., Santomasso B.D., Lacchetti C., Adkins S., Anadkat M., et al. Management of immunerelated adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline update. J Clin Oncol. 2021;39(36):4073–126. DOI: 10.1200/JCO.21.01440

326. Li M., Wong D., Vogel A.S., Sack J.S., Rahma O.E., Hodi F.S., et al. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Hepatology. 2022;75(3):531–40. DOI: 10.1002/hep.32215

327. Delire B., De Martin E., Meunier L., Larrey D., Horsmans Y. Immunotherapy and gene therapy: New challenges in the diagnosis and management of drug-induced liver injury. Front Pharmacol. 2022;12:786174. DOI: 10.3389/fphar.2021.786174

328. Dougan M., Wang Y., Rubio-Tapia A., Lim J.K. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: Expert review. Gastroenterology. 2021;160(4):1384–93. DOI: 10.1053/j.gastro.2020.08.063

329. Peeraphatdit T.B., Wang J., Odenwald M.A., Hu S., Hart J., Charlton M.R. Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation. Hepatology. 2020;72(1):315–29. DOI: 10.1002/hep.31227

330. De Martin E., Michot J.M., Papouin B., Champiat S., Mateus C., Lambotte O., et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68(6):1181–90. DOI: 10.1016/j.jhep.2018.01.033

331. Gauci M.L., Baroudjian B., Zeboulon C., Pages C., Poté N., Roux O., et al. Immune-related hepatitis with immunotherapy: Are corticosteroids always needed? J Hepatol. 2018;69(2):548–50. DOI: 10.1016/j.jhep.2018.03.034

332. Haanen J., Obeid M., Spain L., Carbonnel F., Wang Y., Robert C., et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217–38. DOI: 10.1016/j.annonc.2022.10.001

333. Omori G., Takada K., Murase K., Hayasaka N., Nakamura H., Iyama S., et al. Successful mycophenolate mofetil treatment of a patient with severe steroid-refractory hepatitis evoked by nivolumab plus ipilimumab treatment for relapsed bladder cancer. Clin Case Rep. 2020;9(2):654–9. DOI: 10.1002/ccr3.3597

334. Iwamoto K., Ishitsuka Y., Tanaka R., Sekine I., Fujimoto M. Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events. Eur J Dermatol. 2017;27(3):301–3. DOI: 10.1684/ejd.2017.2973

335. Cheung V., Gupta T., Payne M., Middleton M.R., Collier J.D., Simmons A., et al. Immunotherapy-related hepatitis: Real-world experience from a tertiary centre. Frontline Gastroenterol. 2019;10(4):364–71. DOI: 10.1136/flgastro-2018-101146

336. Riveiro-Barciela M., Muñoz-Couselo E., Fernandez-Sojo J., Diaz-Mejia N., Parra-López R., Buti M. Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies? J Hepatol. 2019;70(3):564–6. DOI: 10.1016/j.jhep.2018.10.020

337. Ziogas D.C., Gkoufa A., Cholongitas E., Diamantopoulos P., Anastasopoulou A., Ascierto P.A., et al. When steroids are not enough in immune-related hepatitis: Current clinical challenges discussed on the basis of a case report. J Immunother Cancer. 2020;8(2):e001322. DOI: 10.1136/jitc-2020-001322

338. Hountondji L., Faure S., Palassin P., Pageaux G.P., Maria A.T.J., Meunier L. Ursodeoxycholic acid alone is effective and safe to treat cholestatic checkpoint inhibitor induced liver injury. Liver Int. 2025;45(5):e70073. DOI: 10.1111/liv.70073

339. Hama N., Abe R., Gibson A., Phillips E.J. Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): Clinical features and pathogenesis. J Allergy Clin Immunol Pract. 2022;10(5):1155–67.e5. DOI: 10.1016/j.jaip.2022.02.004

340. Wei B.M., Fox L.P., Kaffenberger B.H., Korman A.M., Micheletti R.G., Mostaghimi A., et al. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II. Diagnosis and management. J Am Acad Dermatol. 2024;90(5):911–26. DOI: 10.1016/j.jaad.2023.02.073

341. Shiohara T., Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int. 2019;68(3):301–8. DOI: 10.1016/j.alit.2019.03.006

342. Morita C., Yanase T., Shiohara T., Aoyama Y. Aggressive treatment in paediatric or young patients with drug-induced hypersensitivity syndrome (DiHS)/ drug reaction with eosinophilia and systemic symptoms (DRESS) is associated with future development of type III polyglandular autoimmune syndrome. BMJ Case Rep. 2018;2018:bcr2018225528. DOI: 10.1136/bcr-2018-225528

343. Ushigome Y., Kano Y., Ishida T., Hirahara K., Shiohara T. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol. 2013;68(5):721–8. DOI: 10.1016/j.jaad.2012.10.017

344. Avancini J., Maragno L., Santi C.G., Criado P.R. Drug reaction with eosinophilia and systemic symptoms/ drug-induced hypersensitivity syndrome: Clinical features of 27 patients. Clin Exp Dermatol. 2015;40(8):851–9. DOI: 10.1111/ced.12682

345. Giri P.P., Roy S., Bhattyacharya S., Pal P., Dhar S. Dress syndrome with sepsis, acute respiratory distress syndrome and pneumomediastinum. Indian J Dermatol. 2011;56(6):763–5. DOI: 10.4103/0019-5154.91850

346. Martínez-Cabriales S.A., Rodríguez-Bolaños F., Shear N.H. Drug reaction with eosinophilia and systemic symptoms (DReSS): How far have we come? Am J Clin Dermatol. 2019;20(2):217–36. DOI: 10.1007/s40257-018-00416-4

347. Sato K., Hayashi M., Abe K., Fujita M., Takahashi A., Ohira H. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: A case report. Clin J Gastroenterol. 2020;13(6):1310–4. DOI: 10.1007/s12328-020-01178-5

348. Takinami M., Ono A., Kawabata T., Mamesaya N., Kobayashi H., Omori S., et al. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. Invest New Drugs. 2021;39(6):1716–23. DOI: 10.1007/s10637-021-01136-z

349. Stein S., Henze L., Poch T., Carambia A., Krech T., Preti M., et al. IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression. J Hepatol. 2021;74(4):919–30. DOI: 10.1016/j.jhep.2020.10.035

350. Karnsakul W., Arkachaisri T., Atisook K., Wisuthsarewong W., Sattawatthamrong Y., Aanpreung P. Vanishing bile duct syndrome in a child with toxic epidermal necrolysis: An interplay of unbalanced immune regulatory mechanisms. Ann Hepatol. 2006;5(2):116–9.

351. Xie W., Wang Q., Gao Y., Pan C.Q. Vanishing bile duct syndrome with hyperlipidemia after ibuprofen therapy in an adult patient: A case report. BMC Gastroenterology. 2018:18:142. DOI: 10.1186/s12876-018-0869-9

352. Sousa-Pimenta M., Martins Â., Estevinho L.M., Pinho Vaz C., Leite L., Mariz J. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) primary prophylaxis in patients undergoing hematopoietic stem cell transplantation: A network meta-analysis of randomized controlled trials. J Clin Med. 2024;13(22):6917. DOI: 10.3390/jcm13226917

353. Corbacioglu S., Topaloglu O., Aggarwal S. A systematic review and meta-analysis of studies of defibrotide prophylaxis for veno-occlusive disease/sinusoidal obstruction syndrome. Clin Drug Investig. 2022;42(6):465–76. DOI: 10.1007/s40261-022-01140-y

354. Miller M.J., Fontana R.J. Acute liver failure: Do we have a consensus regarding management? Liver Transpl. 2024;30(12):1209–11. DOI: 10.1097/LVT.0000000000000464

355. Fontana R.J., Bari K. Acute liver failure. In: Schiff E.R., Maddrey W.C., Reddy K.R. (eds.). Schiff`s diseases of the liver. John Wiley & Sons; 2017:411–31.

356. Stravitz R.T., Fontana R.J., Karvellas C., Durkals-ki V., McGuire B., Rule J.A., et al. Future directions in acute liver failure. Hepatology. 2023;78(4):1266–89. DOI: 10.1097/HEP.0000000000000458

357. Chughlay M.F., Kramer N., Spearman C.W., Werfalli M., Cohen K. N-acetylcysteine for non-paracetamol drug-induced liver injury: A systematic review. Br J Clin Pharmacol. 2016;81(6):1021–9. DOI: 10.1111/bcp.12880

358. Sanabria-Cabrera J., Tabbai S., Niu H., Alvarez-Alvarez I., Licata A., Björnsson E., et al. N-acetylcysteine for the management of non-acetaminophen drug-induced liver injury in adults: A systematic review. Front Pharmacol. 2022;13:876868. DOI: 10.3389/fphar.2022.876868

359. Singh S., Hynan L.S., Lee W.M.; Acute Liver Failure Study Group. Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci. 2013;58(5):1397–402. DOI: 10.1007/s10620-012-2512-x

360. Lee W.M., Hynan L.S., Rossaro L., Fontana R.J., Stravitz R.T., Larson A.M., et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856–64. DOI: 10.1053/j.gastro.2009.06.006

361. Amjad W., Thuluvath P., Mansoor M., Dutta A., Ali F., Qureshi W. N-acetylcysteine in non-acetaminophen-induced acute liver failure: A systematic review and meta-analysis of prospective studies. Prz Gastroenterol. 2022;17(1):9–16. DOI: 10.5114/pg.2021.107797

362. Moosa M.S., Maartens G., Gunter H., Allie S., Chughlay M.F., Setshedi M., et al. A randomized controlled trial of intravenous N-acetylcysteine in the management of anti-tuberculosis drug-induced liver injury. Clin Infect Dis. 2021;73(9):e3377–83. DOI: 10.1093/cid/ciaa1255

363. Hu P.F., Xie W.F. Corticosteroid therapy in drug-induced liver injury: Pros and cons. J Dig Dis. 2019;20(3):122–6. DOI: 10.1111/1751-2980.12697

364. Yu Y.C., Mao Y.M., Chen C.W., Chen J.J., Chen J., Cong W.M., et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221–41. DOI: 10.1007/s12072-017-9793-2

365. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on liver transplantation. J Hepatol. 2024;81(6):1040–86. DOI: 10.1016/j.jhep.2024.07.032

366. World Health Organization (WHO). The use of the WHO-UMC system for standardised case causality assessment. URL: https://www.who-umc.org/media/2768/standardised-case-causality-assessment.pdf

367. Ganger D.R., Rule J., Rakela J., Bass N., Reuben A., Stravitz R.T., et al.; Acute Liver Failure Study Group. Acute liver failure of indeterminate etiology: A comprehensive systematic approach by an expert committee to establish causality. Am J Gastroenterol. 2018;113(9):1319. DOI: 10.1038/s41395-018-0160-2

368. Germani G., Theocharidou E., Adam R., Karam V., Wendon J., O’Grady J., et al. Liver transplantation for acute liver failure in Europe: Outcomes over 20 years from the ELTR database. J Hepatol. 2012;57(2):288–96. DOI: 10.1016/j.jhep.2012.03.017

369. Ozturk N.B., Herdan E., Saner F.H., Gurakar A. A comprehensive review of the diagnosis and management of acute liver failure. J Clin Med. 2023;12(23):7451. DOI: 10.3390/jcm12237451

370. Reuben A., Tillman H., Fontana R.J., Davern T., McGuire B., Stravitz R.T., et al. Outcomes in adults with acute liver failure between 1998 and 2013: An observational cohort study. Ann Intern Med. 2016;164(11):724– 32. DOI: 10.7326/M15-2211

371. Rao A., Rule J.A., Hameed B., Ganger D., Fontana R.J., Lee W.M. Secular trends in severe idiosyncratic drug-induced liver injury in North America: An update from the Acute Liver Failure Study Group Registry. Am J Gastroenterol. 2022;117(4):617–26. DOI: 10.14309/ajg.0000000000001655

372. Галимова С.Ф. Лекарственные поражения печени (часть I). Трансплантология. 2011;1:13–21. DOI: 10.23873/2074-0506-2011-0-1-13-21

373. Fontana R.J., Bjornsson E.S., Reddy R., Andrade R.J. The evolving profile of idiosyncratic drug-induced liver injury. Clin Gastroenterol Hepatol. 2023;21(8):2088–99. DOI: 10.1016/j.cgh.2022.12.040

374. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical practice guidelines panel; Wendon J., Cordoba J., Dhawan A., Larsen F.S., Manns M., Samuel D., et al. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047–81. DOI: 10.1016/j.jhep.2016.12.003

375. Bernal W., Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525–34. DOI: 10.1056/NEJMra1208937

376. Dawwas M.F., Gimson A.E., Lewsey J.D., Copley L.P., van der Meulen J.H. Survival after liver transplantation in the United Kingdom and Ireland compared with the United States. Gut. 2007;56(11):1606–13. DOI: 10.1136/gut.2006.111369

377. Ozturk N.B., Bartosek N., Toruner M.D., Mumtaz A., Simsek C., Dao D., et al. Approach to liver transplantation: Is there a difference between East and West? J Clin Med. 2024;13(7):1890. DOI: 10.3390/jcm13071890

378. Abaalkhail F.A., Al Sebayel M.I., Shagrani M.A., O’Hali W.A., Almasri N.M., Alalwan A.A., et al. Clinical practice guidelines for liver transplantation in Saudi Arabia. Saudi Med J. 2021;42(9):927–68. DOI: 10.15537/smj.2021.42.9.20210126

379. Оковитый С.В., Райхельсон К.Л., Ахмедов В.А., Вологжанина Л.Г., Гладков О.А., Гречишникова В.Р. и др. Гепатотропная терапия при лекарственных поражениях печени (совещание экспертов). Пермский медицинский журнал. 2025;42(3):58–74. DOI: 10.17816/pmj42358-74

380. Chinese Medical Association Tuberculosis Branch. Guidelines for diagnosis and management of drug-induced liver injury caused by anti-tuberculosis drugs (2024 version). 2024;47(11):1069–90. (In Chinese) DOI: 10.3760/cma.j.cn112147-20240614-00338

381. Туманян С.В., Верещак М.А., Горошинская И.А., Меньшенина А.П., Розенко Д.А., Орос О.В. и др. Функциональное состояние печени и профилактика синдрома эндогенной интоксикации у онкогинекологических больных, оперированных в условиях мультимодальной анестезии. Анестезиология и реаниматология. 2022;5:46–52. DOI: 10.17116/anaesthesiology202205146

382. Qiao F., Chen Q., Lu W., Fang N. Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report. Medicine (Baltimore). 2022;101(27):e29629. DOI: 10.1097/MD.0000000000029629

383. Rong J., Xie Z., Chen E., Ma S., Zhang S., Zhao Y., et al. Fructus Psoraleae-induced severe liver injury and treatment with two artificial liver support systems: A case series study. Ther Apher Dial. 2020;24(3):324–32. DOI: 10.1111/1744-9987.13438

384. Aydemir S., Ustundag Y., Bayraktaroglu T., Tekin I.O., Peksoy I., Unal A.U. Fulminant hepatic failure associated with propylthiouracil: A case report with treatment emphasis on the use of plasmapheresis. J Clin Apher. 2005;20(4):235–8. DOI: 10.1002/jca.20063

385. Скрыпник И.Н., Маслова А.С. Роль S-адеметионина в сопроводительной терапии острых миелобластных лейкемий. Свiт медицини та бiологii. 2019;15(4):159–63. DOI: 10.26724/2079-8334-2019-4-70-159-163

386. Lubarska M., Hałasiński P., Hryhorowicz S., Mahadea D.S., Łykowska-Szuber L., Eder P., et al. Liver dangers of herbal products: A case report of Ashwagandha-induced liver injury. Int J Environ Res Public Health. 2023;20(5):3921. DOI: 10.3390/ijerph20053921

387. Tan E.X., Wang M.X., Pang J., Lee G.H. Plasma exchange in patients with acute and acute-on-chronic liver failure: A systematic review. World J Gastroenterol. 2020;26(2):219–45. DOI: 10.3748/wjg.v26.i2.219

388. Кутепов Д.Е., Пасечник И.Н., Бояринцев В.В. Экстракорпоральные методы детоксикации у больных с печеночной недостаточностью: тридцать лет спустя. Кремлевская медицина. Клинический вестник. 2024;2:110–6. DOI: 10.48612/cgma/ufpr-z5m7-m2ta

389. Narayanan M., Vora R.S., Flynn M.M., Subramanian R.M. The efficacy of albumin dialysis in the treatment of severe cholestatic drug-induced liver injury. Crit Care Explor. 2022;4(8):e0752. DOI: 10.1097/CCE.0000000000000752

390. Stüben B.O., Hoyer D.P., Radunz S., Saner F., Schmidt H., Baba H.A., et al. Idiosyncratic drug-induced liver injury in a healthy patient following PCSK9-inhibitor injection. Case Reports Hepatol. 2024;2024:5556907. DOI: 10.1155/2024/5556907

391. Mertens J.E., Bömmer M.T.C., Regier M.B., Gabriëls G., Pavenstädt H., Grünewald I., et al. Liver injury after selective androgen receptor modulator intake: A case report and review of the literature. Z Gastroenterol. 2024;62(6):935–43. DOI: 10.1055/a-2165-6323

392. Díaz F.C., Sáez-González E., Benlloch S., Álvarez-Sotomayor D., Conde I., Polo B., et al. Albumin dialysis with MARS for the treatment of anabolic steroid-induced cholestasis. Ann Hepatol. 2016;15(6):939–43. DOI: 10.5604/16652681.1222114

393. Bellmann R., Feistritzer C., Zoller H., Graziadei I.W., Schwaighofer H., Propst A., et al. Treatment of intractable pruritus in drug induced cholestasis with albumin dialysis: A report of two cases. ASAIO J. 2004;50(4):387–91. DOI: 10.1097/01.mat.0000132552.58214.00

394. Halegoua-DeMarzio D., Navarro V. Challenges in herbal-induced liver injury identification and prevention. Liver Int. 2025;45(3):e16071. DOI: 10.1111/liv.16071

395. Benić M.S., Nežić L., Vujić-Aleksić V., Mititelu-Tartau L. Novel therapies for the treatment of drug-induced liver injury: A systematic review. Front Pharmacol. 2022;12:785790. DOI: 10.3389/fphar.2021.785790

396. Liu C.T., Chen T.H., Cheng C.Y. Successful treatment of drug-induced acute liver failure with high-volume plasma exchange. J Clin Apher. 2013;28(6):430–4. DOI: 10.1002/jca.21291

397. Sachan D., Verghese J., Saha S., Ilankumaran K., Rela M. Role of therapeutic plasma exchange (TPE) in patients with drug induced liver injury. Vox Sang. 2017;112(S1):5–295. DOI: 10.1111/vox.12530

398. Singh K.A., Kumar S.E., Zachariah U.G., Daniel D., David V., Subramani K., et al. Single-centre experience with low-volume plasma exchange and low-dose steroid to treat patients with idiosyncratic drug-induced acute liver failure. J Clin Exp Hepatol. 2024;14(2):101303. DOI: 10.1016/j.jceh.2023.11.003

399. Regev A., Avigan M.I., Kiazand A., Vierling J.M., Lewis J.H., Omokaro S.O., et al. Best practices for detection, assessment and management of suspected immunemediated liver injury caused by immune checkpoint inhibitors during drug development. J Autoimmun. 2020;114:102514. DOI: 10.1016/j.jaut.2020.102514

400. FDA Guidance for Industry. Drug-induced liver injury: Premarketing clinical evaluation. Silver Spring, MD; 2019.

401. Papay J.I., Clines D., Rafi R., Yuen N., Britt S.D., Walsh J.S., et al. Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol. 2009;54(1):84–90. DOI: 10.1016/j.yrtph.2009.03.003

402. Cajanding R.J.M. MDMA-associated liver toxicity: Pathophysiology, management, and current state of knowledge. AACN Adv Crit Care. 2019;30(3):232–48. DOI: 10.4037/aacnacc2019852

403. Weber S., Gerbes A.L. Update on herbal and dietary supplement-induced liver injury: Current gaps and future directions. Hepatobiliary Surg Nutr. 2023;12(5):752–5. DOI: 10.21037/hbsn-23-329

404. Ye J.H., Ho Y.F., On A.W., Chen W.W., Huang Y.M., Huang W.I., et al. Trends in reporting drug-associated liver injuries in Taiwan: A focus on amiodarone. Int J Clin Pharm. 2018;40(4):911–20. DOI: 10.1007/s11096-018-0698-5

405. Uetake H., Sugihara K., Muro K., Sunaya T., Hori-uchi-Yamamoto Y., Takikawa H. Clinical features of Regorafenib-induced liver injury in Japanese patients from postmarketing experience. Clin Colorectal Cancer. 2018;17(1):e49–58. DOI: 10.1016/j.clcc.2017.09.004

406. Björnsson E.S., Andrade R.J. Long-term sequelae of drug-induced liver injury. J Hepatol. 2022;76(2):435– 45. DOI: 10.1016/j.jhep.2021.10.011

407. Cheng H.S., Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: Utility of transient elastography. Psoriasis (Auckl). 2018;8:21–9. DOI: 10.2147/PTT.S141629

408. Neri S., Signorelli S. Role of ademetionine (S-adenosylmethionine) in cyclosporine-induced cholestasis. Clin Drug Invest. 2002;22(3):191–5. DOI: 10.2165/00044011200222030-00006

409. Vincenzi B., Santini D., Frezza A.M., Berti P., Vespasiani U., Picardi A., et al. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: A retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Expert Opin Drug Saf. 2011;10(3):345–9. DOI: 10.1517/14740338.2011.562888

410. Vincenzi B., Daniele S., Frezza A.M., Berti P., Vespasiani U., Picardi A., et al. The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: A retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen. Support Care Cancer. 2012;20(1):135–9. DOI: 10.1007/s00520-010-1078-4

411. Baniasadi S., Eftekhari P., Tabarsi P., Fahimi F., Raoufy M.R., Masjedi M.R., et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol. 2010;22(10):1235–8. DOI: 10.1097/MEG.0b013e32833aa11b

412. Горошко А.И., Щелкунов А.И., Симонова Н.В. Клиническая эффективность ремаксола для профилактики гепатотоксических осложнений противотуберкулезной химиотерапии. Экспериментальная и клиническая фармакология. 2025;88(3):22–8. DOI: 10.30906/0869-2092-2025-88-3-22-28

413. Akkahadsee P., Sawangjit R., Phumart P., Chaiyakunapruk N., Sakloetsakun D. Systematic review and network meta-analysis of efficacy and safety of interventions for preventing anti-tuberculosis drug induced liver injury. Sci Rep. 2023;13(1):19880. DOI: 10.1038/s41598-023-46565-3

414. Cheng S.L. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur Respir J. 2016;48(Suppl. 60):PA2716. DOI: 10.1183/13993003.congress-2016.PA2716

415. Li X., Zhou J., Chen S., Guan M., Wang Y., Zhao L., et al. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res. 2014;42(4):906–14. DOI: 10.1177/0300060514527058

416. Shang W., Feng Y., Li J., Wang X., Xie H., Feng G. Effect of bicyclol tablets on drug induced liver injuries after kidney transplantation. Open Med (Wars). 2017;12:62–9. DOI: 10.1515/med-2017-0012

417. Kojima M., Kamoi K., Ukimura O., Fujito A., Nakao M., Tanaka S., et al. Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: A preliminary study. Int J Urol. 2002;9(1):42–6. DOI: 10.1046/j.1442-2042.2002.00412.x

418. Леденцова С.С., Гуляев Н.И., Гордиенко А.В., Гаврилова Н.П., Орешко Л.С., Селиверстов П.В. Меры профилактики возможных осложнений, вызываемых системными ретиноидами, при лечении акне в стандартных схемах. Лечащий врач. 2020;6:85–8. DOI: 10.26295/OS.2020.30.33.015

419. Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю., Лерман О.В., Невзорова В.А., Резник И.И. и др. Исследование РАКУРС: повышение эффективности и безопасности терапии статинами у больных с заболеваниями печени, желчного пузыря и/или путей с помощью урсодеоксихолевой кислоты. Терапевтический архив. 2014;86(12):48–52.

420. Ивашкин В.Т., Драпкина О.М., Маевская М.В., Райхельсон К.Л., Оковитый С.В., Жаркова М.С. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российского общества профилактики неинфекционных заболеваний, Российской ассоциации эндокринологов, Российского научного медицинского общества терапевтов, Национального общества профилактической кардиологии, Российской ассоциации геронтологов и гериатров по неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2025;35(1):94–152. DOI: 10.22416/1382-4376-2025-35-1-94-152

421. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492– 542. DOI: 10.1016/j.jhep.2024.04.031

422. García D.S., Saturansky E.I., Poncino D., Martínez-Artola Y., Rosenberg S., Abritta G., et al. “Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency?” Ann Hepatol. 2019;18(5):765–9. DOI: 10.1016/j.aohep.2019.01.011

423. Shea B., Swinden M.V., Tanjong Ghogomu E., Ortiz Z., Katchamart W., Rader T., et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;2013(5):CD000951. DOI: 10.1002/14651858.CD000951.pub2

424. Федеральный закон от 12 апреля 2010 г. № 61-ФЗ «Об обращении лекарственных средств». URL: http://www.consultant.ru/document/cons_doc_LAW_99350/

425. Федеральный закон от 21 ноября 2011 г. № 323-ФЗ «Об основах охраны здоровья граждан в Российской Федерации». URL: http://www.consultant.ru/document/cons_doc_LAW_121895/

426. Приказ Министерства здравоохранения Российской Федерации от 12 ноября 2012 г. № 906н «Об утверждении порядка оказания медицинской помощи населению по профилю «Гастроэнтерология». Зарегистрировано в Минюсте России 21 января 2013 г. № 2664. URL: http://www.consultant.ru/document/cons_doc_LAW_141611/

427. Keays R., Harrison P.M., Wendon J.A., Forbes A., Gove C., Alexander G.J., et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: A prospective controlled trial. BMJ. 1991;303(6809):1026–9. DOI: 10.1136/bmj.303.6809.1026

428. Chiew A.L., Gluud C., Brok J., Buckley N.A. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev. 2018;2(2):CD003328. DOI: 10.1002/14651858.CD003328.pub3

429. Buckley N., Eddleston M. Paracetamol (acetaminophen) poisoning. BMJ Clin Evid. 2007;2007:2101.

430. Niu H., Atallah E., Alvarez-Alvarez I., Medina-Caliz I., Aithal G.P., Arikan C., et al. Therapeutic management of idiosyncratic drug-induced liver injury and acetaminophen hepatotoxicity in the paediatric population: A systematic review. Drug Saf. 2022;45(11):1329–48. DOI: 10.1007/s40264-022-01224-w

431. Barkholt L., Remberger M., Hassan Z., Fransson K., Omazic B., Svahn B.M., et al. A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(9):785–90. DOI: 10.1038/sj.bmt.1705969

432. Van Asseldonk D.P., Crouwel F., Seinen M.L., Scheffer P.G., Veldkamp A.I., de Boer N.K., et al. Exploring the role of oxidative stress and the effect of N-acetylcysteine in thiopurine-induced liver injury in inflammatory bowel disease: A randomized crossover pilot study. Basic Clin Pharmacol Toxicol. 2024;134(4):507–18. DOI: 10.1111/bcpt.13978

433. Jaiswal P., Attar B.M., Yap J.E., Devani K., Jaiswal R., Wang Y., et al. Acute liver failure with amiodarone infusion: A case report and systematic review. J Clin Pharm Ther. 2018;43(1):129–33. DOI: 10.1111/jcpt.12594

434. Farazi A., Sofian M., Jabbariasl M. Efficacy of N-acetylcysteine on prevention of antituberculosis drug-induced hepatotoxicity. World J Med Sci. 2015;12(4):413–8. DOI: 10.5829/idosi.wjms.2015.12.4.10114

435. Singh A.K., Verma S., Kumar M.P., Soni H., Sharma S., Sharma S., et al. Appropriate chemopreventive strategy for anti-tubercular therapy related liver injury is unsettled: Results from a systematic review and network meta-analysis. Expert Rev Clin Pharmacol. 2020;13(11):1253–62. DOI: 10.1080/17512433.2020.1835468

436. Ahmed S., Rao N.A. Role of N-acetylcysteine (NAC) in preventing development of anti tuberculosis therapy (ATT) induced liver injury in pulmonary tuberculosis (PTB) patients, a simple randomized single blind clinical trial. Eur Respir J. 2020;56(Suppl. 64):5301. DOI: 10.1183/13993003.congress-2020.5301

437. Sukumaran D., Usharani P., Paramjyothi G.K., Subbalaxmi M.V.S., Sireesha K., Abid Ali M. A study to evaluate the hepatoprotective effect of N-acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life. Indian J Tuberc. 2023;70(3):303–10. DOI: 10.1016/j.ijtb.2022.05.012

438. Tincu R., Cobilinschi C., Tomescu D., Ghiorghiu Z., Macovei R. P331 Benefits of L-carnitine in valproic acid induced encephalopathy. Crit Care. 2016;20(Suppl. 2):94. DOI: 10.1186/s13054-016-1208-6

439. Hatamkhani S., Khalili H., Karimzadeh I., Dashti-Khavidaki S., Abdollahi A., Jafari S. Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: A randomized, clinical trial. J Gastroenterol Hepatol. 2014;29(5):997–1004. DOI: 10.1111/jgh.12474

440. Овчаренко Л.С., Вертегел А.А., Андриенко Т.Г. Терапия проявлений гепатотоксичности при применении цефтриаксона у детей с патологией респираторного тракта. Современная педиатрия. 2013;1:60.

441. Борзакова С.Н., Аксенова В.А., Рейзис А.Р. Апоптоз лимфоцитов при лекарственно-индуцированных поражениях печени на фоне туберкулеза у детей. Доктор.Ру. 2012;9:67–73.

442. Борзакова С.Н., Рейзис А.Р. Лекарственные поражения печени у детей с туберкулезом. Экспериментальная и клиническая гастроэнтерология. 2016;1:49–53. [

443. Курманова Г.М., Курманова К.Б., Садыкова Ш.С. Эффекты урсодезоксихолевой кислоты при стандартной противовирусной терапии больных хроническим гепатитом С и В. Экспериментальная и клиническая гастроэнтерология. 2015;9:99–104.

444. Андреев Д.Н., Маев И.В., Дичева Д.Т., Бектемирова Л.Г. Эффективность урсодезоксихолевой кислоты в рамках минимизации гепатотоксичного потенциала эрадикационной терапии инфекции Helicobacter pylori. Лечащий врач. 2020;4:51. DOI: 10.26295/OS.2020.78.94.009

445. Shahramian I., Bazi A., Mostafaee R., Mohammadi M.H. Protective effects of ursodeoxycholic acid on valproic acid induced hepatotoxicity in epileptic children with recurrent seizure; a double-blinded randomized clinical trial. Pharmaceutical Sciences. 2020;26(1):25–31. DOI: 10.34172/PS.2019.62

446. Mohammed Saif M., Farid S.F., Khaleel S.A., Sabry N.A., El-Sayed M.H. Hepatoprotective efficacy of ursodeoxycholic acid in pediatrics acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2012;29(7):627–32. DOI: 10.3109/08880018.2012.713083

447. Bordbar M., Shakibazad N., Fattahi M., Haghpanah S., Honar N. Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia. Turk J Gastroenterol. 2018;29(2):203–9. DOI: 10.5152/tjg.2018.17521

448. Santini D., Vincenzi B., Massacesi C., Picardi A., Gentilucci U.V., Esposito V., et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res. 2003;23(6D):5173–9.

449. Суханов Д.С. Эффективность гепатопротекторного действия и оценка риска при использовании реамберина, ремаксола и адеметионина у больных туберкулезом органов дыхания с лекарственными поражениями печени. Терапевтический архив. 2012;84(11):26–9.

450. Суханов Д.С., Павлова М.В., Виноградова Т.И. Клиническая эффективность инфузионных растворов на основе янтарной кислоты в терапии поражений печени, вызванных противотуберкулезными препаратами. Туберкулез и болезни легких. 2013;90(8):050–6.

451. Кляритская И.Л., Максимова Е.В. Тактика ведения пациентов с онкологическими заболеваниями и лекарственными поражениями печени. Крымский терапевтический журнал. 2013;1:71–82.

452. Скрипник І.М., Маслова А.С. Вплив S-адеметіоніну на вміст аргініну і його метаболітів у хворих на хронічну лімфоцитарну лейкемію на фоні хіміотерапії. Семейная медицина. 2020;3:20–3. DOI: 10.30841/2307-5112.3.2020.211188

453. Угрюмова Е.В. Адеметионин в цитостатической терапии псориаза. Вестник дерматологии и венерологии. 2010;2:52–6.

454. Hisanaga M., Utsumi S., Miyamoto S., Okazaki A., Tsukamoto S. Abnormality of liver function in patients treated with antiepileptic drug and a trial of polyene phosphatidyl choline treatment for these patients. Folia Psychiatr Neurol Jpn. 1980;34(3):318–9. DOI: 10.1111/j.1440-1819.1980.tb01551.x

455. Слюндин Д.Г., Алехнович А.В., Иванов В.Б., Ливанов А.С., Анучин В.В. Фармакологическая коррекция гипераммониемии при криминальных отравлениях клозапином. Medline. ru. 2010;11:518–25.

456. Остапенко Ю.Н., Иванов В.Б., Алехнович А.В., Ливанов А.С. Гипераммониемия при острых отравлениях психотропными средствами и возможность ее коррекции. Consilium Medicum. 2006;8(7):10–3.

457. Scheller A., Jacob U., Keilhauer R. Verbesserung der Zytostatikatoleranz durch Ornithinaspartat. Der Bayrische Internist. 1998;1:54–60.

458. Солдатова Г.С., Поспелова Т.И., Чечерина А.А. Гипераммониемия у пациентов с лимфопролиферативными заболеваниями. Гематология и трансфузиология. 2022;67(2):300–1.

459. Мацишевская И.В. Опыт использования ОРНИТОКСА (L-орнитин-L-аспартата) в практике отделения химиотерапии Винницкого областного клинического онкологического диспансера для оптимизации проведения химиотерапии. Клінічна Онкологія. 2011;4(4):1–3.

460. Суханов Д.С., Иванов А.К., Романцов М.Г., Коваленко А.Л. Лечение гепатотоксических осложнений противотуберкулезной терапии сукцинатсодержащими препаратами. РМЖ. 2009;6:22–5.

461. Шевырева Е.В., Иванов А.К., Суханов Д.С., Мурзина А.А. Гепатопротекторная терапия ремаксолом у больных туберкулезом и ВИЧ-инфекцией в дневном стационаре противотуберкулезного диспансера. Антибиотики и химиотерапия. 2012;57(7–8):31–7.

462. Иванова М.И., Матякин Г.Г., Иванов В.М., Шейкин М.В., Коваленко А.Л., Петров А.Ю. Возможности сопроводительной терапии злокачественных новообразований орофарингеальной области. Онкология. Журнал им. П.А. Герцена. 2023;12(5):34–8. DOI: 10.17116/onkolog20231205134

463. Волчегорский И.А., Новоселов П.Н., Ушкарева Э.В. Влияние ремаксола на эффективность стандартного лечения больных инфильтративным туберкулезом легких. Терапевтический архив. 2016;88(3):73–8. DOI: 10.17116/terarkh201688373-78

464. Матякин Г.Г., Иванов В.М., Иванова О.В., Шейкин М.М. Токсико-модифицирующее действие ремаксола при лечении местно-распространенного рака слизистой полости рта. Стоматология. 2013;92(6):12–5.

465. Шовкун Л.А., Кудлай Д.А., Кампос Е.Д., Николенко Н.Ю., Севостьянова Т.А., Франчук И.М. Терапия предупреждения и купирования гепатотоксических реакций у больных туберкулезом с лекарственной устойчивостью. Туберкулез и болезни легких. 2025;103(2):13–21. DOI: 10.58838/2075-1230-2025-103-2-13-21